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Abstract 
Rtt109 is a fungal-specific histone acetyltransferase that catalyzes histone H3 
lysine 56 acetylation and is a promising antifungal drug target. To identify novel Rtt109 
inhibitors as potential drug scaffolds, we employed in vitro high throughput screening 
(HTS) and various computer-assisted strategies, including molecular dynamics, docking, 
three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis, 
pharmacophore modeling, and Support Vector Machine (SVM) mining. An initial 
experimental screening of 82,861 compounds (HTS1) yielded hits with activity ranging 
from 0.49 – 17.5 µM against Rtt109. The molecular dynamics simulation of Rtt109 
suggested that the histone lysine tunnel, a potential inhibitor binding site, was not flexible 
and thus the use of a rigid protein structure of Rtt109 was appropriate for docking studies. 
From a virtual screen using Surflex-Dock, we have identified 878 additional compounds 
as potential hits, with predicted Kd values of 0.1 nm or lower. Based on preliminary 
experimental data from HTS1, validated pharmacophore maps were developed and used 
to pinpoint potential Rtt109 ligand-receptor interactions. 3D-QSAR CoMFA and 
CoMSIA models that were also derived from the hit series generated in the initial 
experimental HTS display high self-consistency (r2 = 0.985 [CoMFA] and r2 = 0.976 
[CoMSIA]) and robust internal predictivity (rcv2 = 0.754 [CoMFA] and rcv2 = 0.654 
[CoMSIA]). Importantly, key features identified in both the pharmacophore hypotheses 
and the 3D-QSAR models agreed well with each other and with experimentally defined 
structural features in the Rtt109 lysine-binding tunnel. In addition, our optimized SVM 
models demonstrated high predictive power against the external test sets for Rtt109 with 
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accuracy of 91.1%. We also identified novel features with significant differentiating 
ability to separate Rtt109 inhibitors from non-inhibitors. 
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CHAPTER 1: 
INTRODUCTION 
?
1.1 Fungal Infections 
 Fungi are well known as a widespread threat to plant species.1 Fungal infections in 
potatoes, rice, wheat, and soybean cause economic losses and present a growing threat to 
food security. Invasive tree diseases have led to the loss of ~100 million elm trees in the 
United States and the United Kingdom, with economic cost for the loss of wood and also 
increased carbon release.2 In addition, fungal infections have caused population declines 
in bats, frogs and soft corals, bees, Tilapia fish, and so on. For example, during March 
2007, bats in New York State died in great numbers because of the white nose syndrome 
caused by fungal infections.3 The fungus responsible for causing the deadly white nose 
syndrome has also been found at Soudan Underground Mine State Park and 
Forestville/Mystery Cave State Park, two of Minnesota's largest bat caves.4 Until 2007, 
some areas of central America had lost more than 40% of amphibian species due to 
fungal infections, leading to ecosystem-level changes.5 
Fungal infections including systemic fungal infections (mycoses), also pose an 
increasing threat to human health, particularly in cases of immunocompromised 
individuals undergoing corticosteroid, immunosuppressant and/or antimetabolite therapy 
for organ transplantation, cancer, azotemia, diabetes mellitus, or AIDS.6-8 Superficial 
infections which affect ~25% of the population worldwide are the most common human 
fungal diseases.9 These infections often lead to athlete’s foot, ringworm, and infection of 
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the nails. While superficial fungal infections are usually not life-threatening in 
immunocompetent hosts, systemic mycoses affecting severely compromised patients 
often exhibit acute presentations with rapidly progressive pneumonia and/or 
extrapulmonary dissemination. The mortality rates of patients can exceed 50% in the 
majority of systemic mycoses, and approach 100% in extrapulmonary invasive 
aspergillosis.10-12 Although major advances have been made in combating fungal 
infections,13 the design of fungal-specific therapeutics is not trivial because fungal 
pathogens are eukaryotic and share key biological processes with humans and other 
animals. Many currently available antifungal drugs exhibit an array of adverse effects due 
to lack of selectivity; in the case of amphotericin B, the standard therapy for most life-
threatening systemic mycoses, these may include cardiac arrest, encephalopathy, 
neuropathy, renal damage, liver failure, thrombophlebitis and hearing loss.14, 15 In 
addition, the rapid evolution of drug resistance has compromised the effectiveness of 
many currently available antifungal therapies, such as the widely used azole derivatives 
fluconazole and ketoconazole, that target lanosterol demethylase in the fungal ergosterol 
pathway.14, 16-18 Undesirable drug-drug interactions due to interference with the CYP3A4, 
CYP2C9, and CYP2C19, also restrict the use of the azole antifungal agents.19 Given the 
rising incidence of life-threatening systemic mycoses (mainly due to increasing numbers 
of immunocompromised individuals), there is a critical unmet need for new antifungal 
therapeutic treatments that selectively target fungi and can bypass current fungal 
resistance pathways. 
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1.2 Histone Acetyltransferase 
Histones are the common components of chromosomes and are the most 
conservative proteins known. There are five types of histones: H1, H2A, H2B, H3, and 
H4. The histone H1 serves as a linker that interacts with DNA and stabilizes the highly 
ordered assembly of DNA helix and proteins.20 One-hundred-and-forty-seven base pairs 
of DNA are wrapped around an octamer of core histones H2A, H2B, H3 and H4 to form 
the basic unit of chromatin, nucleosome.21 Histones can undergo post-translational 
modifications to both their structured core domains and less structured tail domains, 
including more than 60 different residues on histones. At least eight different classes of 
modifications have been identified on histones: acetylation, methylation, 
phosphorylation, ubiquitylation, sumoylation, ADP ribosylation, deimination, and proline 
isomerization.22 The dynamic modifications of histones are involved in the regulation of 
transcription, DNA repair, and chromosome condensation during different cell 
development stages.23 
 Acetylation is one of the most widely studied histone modifications. Histone 
acetyltransferases (HATs) are the enzymes responsible for the transfer of an acetyl group 
from AcCoA to histones. On the other hand, histone deacetylases (HDACs) catalyze the 
removal of acetyl groups so that histone acetylation is a reversible process.24 Generally, 
acetylation occurs at the lysine residues of histones. The acetylation catalyzed by HATs 
results in the neutralization of the positively charged lysine residue of histone, which 
interrupts the interactions between the lysine residue and the negative charged DNA 
phosphate backbone.25 As a result, chromatin is more extended and more accessible for 
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transcriptional factors, and gene transcription is promoted. 
 
1.3 Histone Acetyltransferase Families 
HATs are a diverse set of enzymes that can be classified into different families 
based on their catalytic domains and their sequence homology. The GNAT (Gcn5-related 
N-acetyltransferase) family is one of the main families, which includes Gcn5 (KAT2A), 
PCAF (KAT2B), Elp3 (KAT9), Hat1, Hpa2, and so on. HATs in this family are 
transcriptional activators and share more than 70% sequence homology. Another 
predominant family is the MYST family. The members of the MYST family are Morf 
(KAT6B), Ybf2 (Sas3), Sas2, Tip60 (KAT5), and so on. These HATs are involved in the 
DNA repair, gene anti-silencing, and dosage conpensation.26 Other HATs include p300 
(KAT3A), CBP (KAT3B), Taf1, and a number of steroid receptor co-activators such as 
p600 (KAT13C) and CLOCK (KAT13D). Like Gcn5, p300/CBP serve as co-activators 
for gene transcription. They interact with DNA-bound transcription factors including 
E1A and phosphorylated CREB, but not directly with DNA.26, 27 
 
1.4 Rtt109  
 
Rtt109 (Regulator of Ty1 Transposition 109) is a fungal-specific histone 
acetyltransferase that acetylates histone H3 lysine residues to promote gene activation 
and genome stability.28 Gene deletion experiments29, 30 have demonstrated that Rtt109 is 
essential for fungal pathogenicity: C. albicans Rtt109-/- mutant cells were found to be 
significantly less pathogenic in mice and more susceptible to in vitro phagocytosis than 
wild-type cells, as well as hypersensitive to genotoxic agents.29 Rtt109 is structurally 
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similar to the mammalian HAT enzyme p300/CBP31 but generally demonstrates little to 
no sequence homology with respect to other HATs. The specificity and catalytic activity 
of Rtt109 require a unique association with one of two histone chaperones, Vps75 and 
Asf116, 32, 33, an association not seen elsewhere in the HAT family. In the absence of 
chaperone proteins, Rtt109 is an inefficient histone acetyltransferase with a kcat value of 
2.3 ± 0.7 × 10-3 s-1 for histone H3.34 When Rtt109 and Vps75 form a stable complex (Kd 
= 10 ± 2 nM), the kcat value of the complex is 0.62±0.03 s-1 for full-length histone H3 and 
0.11 ± 0.01 s-1 for H3 peptide substrate.35 More detailed kinetic values for Rtt109 and 
Rtt109-Vps75 complex are summarized in Table 1.1, even though kinetic values vary 
slightly in assays done by different groups.36 Further steady-state kinetic analyses 
indicate that Vps75 activates Rtt109 by enhancing catalytic turnover but not by 
increasing the binding affinity for histone.  The enhancing rate of acetyl transfer occurs 
through the stabilization of the catalytically active conformation of Rtt109 by Vps75. 
Two electrostatic contact sites including residues Glu374, Glu378, Glu299, Glu300, and 
Asp301 of Rtt109 have been demonstrated to be important for Rtt109 catalytic activation. 
However, they are not the major reason for the high affinity between Rtt109 and Vps75. 
The hydrophobic interactions instead, likely involving the unstructured loop of Rtt109 
(residues 130-179), mainly contribute to the overall high binding affinity.34 For Rtt109-
Asf1 complex, the kcat value is 0.021 ± 0.002 s-1 and the kcat/Km value is 2.0 ± 0.5 × 104 
M-1 s-1 for histone H3/H4 substrates. Notably, unlike Rtt109-Vps75, Rtt109-Asf1 does 
not efficiently acetylate H3 but becomes efficient in the presence of H4, indicating the 
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interactions between Asf1 and H4 facilitate the proper binding or positioning of H3 for 
acetylation.37?
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Table 1.1. Kinetics of acetylation by Rtt109 and Rtt109-Vps7536 
Enzyme  Substrate  kcat (s-1)  Km (µM) kcat / Km (M-1 s-1) 
H3 0.21 ± 0.04  5.8 ± 0.8  3.5 ± 0.9 × 104 
H3-H4  0.11 ± 0.05  1.4 ± 0.4  8.4 ± 2 × 104 
H3 tail peptide  0.13 ± 0.04  75 ± 15  1.8 ± 0.5 × 103 
Rtt109-Vps75  
AcCoA  0.19 ± 0.01  1.0 ± 0.2  1.9 ± 0.4 × 105 
H3  0.0033 ± 0.0003  8.1 ± 0.1  4.3 ± 0.2 × 102 
H3-H4  0.0044 ± 0.0009  2.9 ± 0.6  1.5 ± 0.6 × 103 
H3 tail peptide  0.0014 ± 0.0004  83 ± 29  1.7 ± 1 × 101 
Rtt109  
AcCoA  0.0017 ± 0.0001  0.3 ± 0.09  5.2 ± 2 × 103 
?
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In addition, autoacetylation of Lys290 of Rtt109 is required for its catalysis. This 
autoacetylation stabilizes the interaction between the core protein acetyltransferase 
domain and the activation domain, and the engagement of the two domains turns Rtt109 
into an active state.38 Rtt109 catalyzes the autoacetylation of Lys290 itself by an 
intramolecular mechanism, meaning the autoacetylation occurs within a single enzyme 
molecule. Vps75 is not required for the autoacetylation and shows no apparent effects on 
the reaction rate and mechanism. Mutational studies demonstrate that autoacetylation 
stimulates histone acetyltransferase activity by enhancing catalytic acetyl transfer and 
increasing AcCoA binding. Both K290Q and K290R mutants, which represent 
unacetylated lysine, exhibit a ~100-fold decrease in kcat of the Rtt109-Vps75 complex and 
a larger than 10-fold decrease in Kd value for AcCoA binding.39 
The catalytic cores, catalytic mechanisms, and substrate specificity of Rtt109 also 
differ significantly from those of other known HATs including p300/CBP.40 Unlike the 
Gcn5/PCAF HAT group, Rtt109 does not contain a key conserved active-site glutamate 
residue;16 two important catalytic residues in p300/CBP (Trp1436 and Tyr1467) are also 
absent in Rtt109. As it is currently understood, the Rtt109 mechanism of action does not 
follow the ordered Bi-Bi ternary complex mechanism utilized by Gcn5/PCFA33, the 
ternary ping-pong mechanisms proposed for Esa1 (a member of the MYST family of 
HATs)28, or the Theorell-Chance mechanism for p300/CBP.41 Rtt109 instead employs a 
random sequential mechanism in which the histone H3 and AcCoA moieties bind to the 
Rtt109-Vps75 complex in no particular order, followed by direct attack of the 
unprotonated histone lysine on AcCoA.42 Finally, Rtt109 is quite selective for the histone 
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H3 lysines 5632, 943, and 2734, while other HATs including p300/CBP exhibit a much 
broader range of substrates (several lysine sites within histone and non-histone 
proteins).42 Taken together, these key structural and mechanistic variances set Rtt109 
apart from human HATs, and indicate that Rtt109 may be a promising target for small-
molecule antifungal drug development. However, no Rtt109 inhibitors are currently 
available as therapeutics; in fact, recent in vitro studies have shown that a series of potent 
p300/CBP inhibitors exhibited only very weak activity against Rtt109.31 
The structure of Rtt109 consists of eight β-strands surrounded by eleven α-helices 
and several loops (Figure 1.1). The Rtt109 surface features a roughly circular aperture 
located between the β-strands β4 and β5, and the surface loops β5-αE and αG-αH.5, 16 
This aperture leads into a hydrophobic tunnel (the histone lysine residue entrance tunnel), 
ending in the acetyl group of AcCoA when bound. On the opposite side of the enzyme, 
the AcCoA binding tunnel is positioned between the N-terminal areas of helices αB and 
αE, and the C-terminal regions of β-strands β4 and β5. In the histone lysine binding 
tunnel, Ser86, Tyr199, Trp222, and Asp288, which are proximal to the acetyl group of 
AcCoA, may function catalytically,31 while Phe84, Tyr199, Pro289, and the sidechains of 
Lys87 and Arg194 may engage in hydrophobic interactions with the aliphatic part of the 
substrate histone lysine residue.31 Single-site mutagenesis studies have shown that 
residues Asp89, Tyr199, Trp222, Asp287 and Asp288 are important for Rtt109 catalysis 
and/or substrate binding,31, 38, 44 suggesting that these residues may be suitable as initial 
targets for inhibitor design. W222F and D89N reduce the apparent Km for both H3 and 
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AcCoA, which leads to a ~25-fold rate decrease. Y199S results in a rate decrease of 
about 10-fold, and D287A has a mild 3-fold rate decrease.47  
So far, not much work has been reported regarding inhibiton pf Rtt109, but there 
is considerable precedence for inhibition of other HATs. Thus, Rtt109 might be a 
promising target for antifugal agents.?
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Figure 1.1. Structure of fungal histone acetyltransferase Rtt109 (PDB code 2ZFN16) 
colored by secondary structure (PyMOL/1.445)   
 
 
?
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1.5 Histone Acetyltransferase Inhibitors 
Dysfunction of HATs is often associated with the development of cancer, 
inflammation, deregulation of neuronal cell plasticity, and so on. In addition, the 
acetylation of HIV Tat protein is found to be necessary for viral pathogenesis, and 
acetylation of histone H3 lysine 56 in Candida albicans helps maintain fungal genome 
stability.24 Thus, HATs are important targets for the development of novel therapeutics 
for cancer, Alzheimer disease, AIDS, and fungal infections.  Investigations of HAT 
inhibitors as potential therapeutical strategies have been reported recently. Although 
various approaches including high-throughput screening and structure-based design have 
been utilized to discover novel inhibitors of HATs, a limited number of inhibitors have 
been identified. The available inhibitors include natural products, bisubstrate inhibitors 
based on AcCoA, and synthetic compounds. In the work described in this disseration, we 
are particularly interested in identifying and developing inhibitors against fungal specific 
histone acetyltransferase as potential antifugal agents, because it has been demonstrated 
that fungal histone acetyltransferase Rtt109 is essential for fungal pathogencity.   
Glycosaminoglycans (GAGs) were reported to be potent inhibitors of p300 and 
PCAF in vitro. Heparin from the GAGs class may serve as an endogenous HAT inhibitor 
to modulate HAT activities. Heparin was shown to cause a significant increase in the 
apparent Km of PCAF for H4 (5.3 ± 1.9 nM in the absence of heparin and 259.7 ± 79.8 
nM in the presence of heparin) and further analysis suggests that heparin inhibits PCAF 
through a competitive-like mechanism with an apparent Ki of ~15 nM.46 Another 
potential endogenous HAT inhibitor is spermidine, a natural polyamine. Administration 
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of spermidine leads to deacetylation of histone H3 via inhibition of histone 
acetyltransferases (HAT). In addition, depletion of endogenous polyamines results in 
hyperacetylation, increased oxidative stress, necrosis, and decreased lifespan.47 
The natural product anacardic acid 1.1 (Figure 1.2) is an ingredient found in 
cashew nut shells that is associated with antitumor activity.  It is reported to inhibit HAT 
activity of PCAF and p300. Its IC50 values against PCAF and p300 are ~5 µM and ~8.5 
µM, respectively. An inhibition kinetics study suggests that anacardic acid is a non-
competitive inhibitor of p300.48 Anacardic acid also inhibits Tip60 in vitro with an IC50 
of 9 µM. It blocks the Tip60-dependent activation of ATM protein kinase that is essential 
for cells to repair and to survive exposure of ionizing radiation and thus sensitizes tumor 
cells to the cytotoxic effects of ionizing radiation.49 Although it is a non-specific inhibitor 
of HATs, anacardic acid provides a template for further modification and development of 
more specific inhibitors of HATs. 
Curcumin 1.2 (Figure 1.2) is a polyphenolic compound from Curcuma longa 
rhizome. Two different HAT assays conducted by Balasubramanyam and co-workers 
demonstrated that the acetylation of histones H3 and H4 by p300/CBP was inhibited by 
curcumin with an IC50 of ~25 µM. However, it did not change the PCAF activity even at 
the concentration of 100 µM and thus shows a certain level of selectivity in the HAT 
family.50 Enzyme kinetics studies indicate that curcumin does not bind to the active sites 
of histone or AcCoA. It instead binds to some allosteric site, which triggers a 
conformational change of p300, leading to a decrease of binding efficiency of histones 
and AcCoA. Curcumin also inhibits p300-mediated acetylation of p53 in vivo, but other 
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HAT-mediated acetylations of p53 are not inhibited by cucumin. In addition, curcumin 
inhibits the acetylation of the HIV-1 transactivator Tat that is important for the HIV 
transcriptional activation and suppresses the proliferation of HIV virus. Thus, curcumin 
may serve as a lead compound in the development of HIV therapeutics. So far, curcumin 
has been evaluated in several clinical trials for the treatment of myeloma, pancreatic 
cancer, chronic psoriasis vulgaris, Alzheimer’s disease, and so on. It is the first small 
molecule with HAT inhibitory activity in clinical studies.51 
Garcinol 1.3 (Figure 1.2), a polyisoprenylated benzophenone derivative from the 
fruit of Garcinia indica, has been shown by Balasubramanyam and co-workers to inhibit 
PCAF with an IC50 of ~5 µM and p300 with an IC50 of ~7 µM. It inhibits the HAT 
activity-dependent chromatin transcription, but not the transcription from a DNA 
template. In addition, garcinol stimulates apoptosis in HeLa cells and human leukemia 
cell lines. The kinetic analysis demonstrates that the inhibition mechanisms of garcinol 
for p300 and PCAF are similar. It behaves as an uncompetitive inhibitor for AcCoA, and 
as a competitive inhibitor for core histones.52 However, interestingly, in another kinetic 
study done by Arifand co-workers garcinol showed competitive inhibition for the AcCoA 
binding site on p300 and noncompetitive inhibition for the histone-binding site.53 A later 
isothermal calorimetric experiment then suggested garcinol binds to two sites on p300. 
Based on further studies using fluorescence, docking, and mutations, the authors 
proposed that the catechol hydroxy moieties provide key interactions with the AcCoA 
binding site and the isoprenoid groups play an important role in the binding to an 
allosteric site.53 
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Epigallocatechin-3-gallate (EGCG) 1.4 (Figure 1.2), the major polyphenol found 
in green tea extract, has been reported to be an inhibitor of p300 and CBP with IC50 
values of ~30 µM and ~50 µM, respectively. It also shows inhibitory activities against 
PCAF (IC50 of ~60 µM) and Tip60 (IC50 of ~70 µM).54 Kinetic studies demonstrate that 
EGCG does not bind to the active site of histone and it uncompetitively inhibits 
p300/CBP. EGCG prevents the hyperacetylation of p65 in vitro, and represses tumor 
necrosis factor α (TNFα)–induced NF-κB activation. EGCG also reduces the release of 
IL-6 by cell cultures exposed to different inflammatory stimuli. It generally inhibits the 
inflammatory responses and thus may contribute to the prevention and treatment of 
diseases such as chronic obstructive pulmonary disease and asthma.54 
 Plumbagin (PTK-1) 1.5 (Figure 1.2), isolated from Plumbago rosea root extract, 
potently inhibits p300 in vivo, but not PCAF. It inhibits the HAT activity of the 
catalytically active domain with an IC50 of ~2 µM while inhibiting the full-length p300 
with an IC50 of ~20 µM. The kinetic analysis of the inhibition of p300 by PTK-1 shows a 
noncompetitive pattern with both histones and AcCoA. Docking and mutational studies 
conducted by Ravindra?and co-workers demonstrated that the hydroxyl group of PTK-1 
was essential for its HAT inhibition and it was proposed that it forms a H-bond to the key 
residue K1358 in p300.55 Further structure-activity relationship studies illustrated that the 
absence of a hydroxyl group led to inactive derivatives of PTK-1.  
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Figure 1.2. Natural products with HAT inhibitory properties 
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Bisubstrate inhibitors are the first series of synthetic HAT inhibitors. These 
inhibitors are often derivatives of CoA, covalently connected to the substrate peptides 
with different chain lengths. An acetyl bridge between the amine substrate and CoA has 
been demonstrated by Lau and co-workers to be among the most effective linkers 
between the two and thus most of these bisubstrate inhibitors are designed with the acetyl 
bridge. Lys-CoA 1.6 (Figure 1.3) is one of the bisubstrate inhibiors that inhibit p300 
selectively with an IC50 of ~0.5 µM, whereas its IC50 for PCAF is ~200 µM.56 H3-CoA-
20 1.7 (Figure 1.3) proved to be potent at inhibiting PCAF with an IC50 of ~0.3 µM, but 
showed little potency against p300 with an IC50 of ~200 µM. Different from expected, 
neither CoA-SH or H3-20 peptide is a potent HAT inhibitor. H4K16CoA 1.8 (Figure 1.3) 
was one of the most potent inhibitor of Tip60 with an IC50 of ~17.6 µM. It also shows 
inhibitory activities against Esa1 with an IC50 of ~5.5 µM, against p300 with an IC50 of 
~6.6 µM, and against PCAF with an IC50 of ~58.5 µM. The kinetic studies indicate that 
H4K16CoA is a competitive inhibitor of Esa1 versus AcCoA and noncompetitive 
inhibitor versus H4 peptide substrate.57 Spd-CoA 1.9 (Figure 1.3) is another p300/CBP 
inhibitor. It inhibits histone acetylation, DNA synthesis, and acetylation-dependent DNA 
repair. In order to increase cell uptake, compound 1.10 was designed with truncated CoA 
moiety to eliminatethe negative charges. It is slightly more potent against p300/CBP in 
vitro than compound 1.9, and it also suppresses histone acetylation in vivo.58 
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Figure 1.3. Bisubstrate HAT inhibitors 
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 The γ-butyrolactone scaffold was chosen by Biel and co-workers for the 
development of new HAT inhibitors because of its recurrent structure in many natural 
products with a wide spectrum of biological activities. The α-methylene-γ-butyrolactone 
derivatives 1.11 -1.13 (Figure 1.4) display weak inhibition of CBP (IC50values ranging 
from 0.5mM to 2mM), whereas compound 1.11 shows stronger inhibitory activity against 
Gcn5 with an IC50 value of 100 µM. Based on the kinetic studies, the inhibition of Gcn5 
by compound 1.11 shows no time dependence. Thus compound 1.11 is a reversible 
inhibitor of Gcn5. A Michael addition of nucleophilic groups of the Gcn5 binding site to 
the α, β-unsaturated carbonyl moiety of compound 1.11 is unlikely to occur.59 
 The quinoline derivatives 1.14 and 1.15 (Figure 1.4) were designed by Mai and co-
workers using anacardic acid as the template. Both compounds are able to reduce the 
yeast cell growth and the Gcn5-dependent gene transcription both in basal and in 
activated conditions. The histone H3 acetylation levels are highly decreased by the 
treatment of 0.6 mM 1.14 and 1.5 mM 1.15.60 
Thirty-five N-substituted isothiazolones were identified by Stimson and co-
workers as p300 and PCAF inhibitors via a FlashPlate high throughput screening.61 
Compound 1.16 (CCT077791) and Compound 1.17 (CCT077792) reduced cellular 
acetylation in a time-and-concentration dependent manner in human colon tumor cell 
lines. The chemical reactivity of these compounds is related to their HAT inhibitory 
activity, as indicated by the loss of such activity in the presence of DTT. It is proposed 
that isothiazolones react with the side chain of cysteine groups to form a new covalent 
bond with consequent loss of catalytic activity of the HATs. The high reactivity and 
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considerable off-target effects of these compounds may restrict their use as therapeutics. 
However, they provide a starting point for the development of related inhibitors.  
Structure-based in silico screening conducted by Bowers and coworkers led to the 
discovery of the compounds C464 1.18, C375 1.19, and C146 1.20 (Figure 1.4) as p300 
inhibitors.62 About 500,000 commercially available compounds were docked into the 
lysine-CoA binding site of the p300 crystal structure and 194 highest-scoring compounds 
were purchased and tested experimentally. Among the 194 compounds, compound 1.18, 
1.19, and 1.20 display relatively potent inhibitory activity against p300. The specificity of 
each of the three compounds were then analyzed versus six other HATs including Gcn5, 
PCAF, MOZ, and Rtt109. Compound 1.18 was highly selective in inhibiting p300 while 
compound 1.19 and compound 1.20 were less selective. Both compounds 1.19 and 1.20 
showed inhibitory activity against at least one of the other HATs with comparable 
potency to that of p300. In the kinetic studies, compound 1.18 showed competitive 
inhibition of p300 versus AcCoA with a Ki value of 400 nM and a noncompetitive pattern 
versus H4-15 peptide substrate. Compound 1.19 proved to be a classical noncompetitive 
inhibitor of p300 with a Ki of 4.8 µM. Compound 1.20 was found to be a competitive 
inhibitor of p300 versus H4-15 peptide substrate. On the other hand, compound 1.20 was 
a pseudocompetitve inhibitor versus AcCoA with a Ki of 4.7 µM, indicating a more 
complex interaction with p300 than a bisubstrate analog. In the computational model, 
compound 1.18 was predicted to H-bond with the side chains of Thr1411, Tyr1467, 
Trp1466, and Arg1410 in the lysine-CoA binding site. Site-directed p300 mutations of 
each of these residues resulted in at least 2-fold increase in the apparent Ki of compound 
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1.18 and confirmed the binding mode of compound 1.18. Further structure-activity 
relationship investigations demonstrated that the shape and/or electronic properties of the 
conjugated system in compound 1.18 were important for its activity. Replacing the para-
carboxylic acid group of compound 1.18 with other hydrogen bond acceptors was well 
tolerated at both the para- and meta- positions. The nitrophenyl group could be replaced 
by a methylbenzoate or a cyanophenyl functionality. However, replacement of 
nitrophenyl moiety with a pyridine ring led to loss of its inhibition against p300.  
  22 
Figure 1.4. Synthetic small molecules as HAT inhibitors 
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1.6 Development of Rtt109 Inhibitors 
Besides our own efforts to be described, the Kaufman group has also contributed 
to the discovery and development of novel Rtt109 inhibitors. Kaufman and co-workers 
identified 537 initial hits with percentage inhibition larger than 50% at 25 µM from 
363,843 molecules using a fluorescence-based assay.63 Among them, 449 molecules were 
re-tested in an 8-point, 2-fold dose titration using optical absorbance detection, which 
was designed to eliminate non-specific fluorescence quenchers. Eighty-two compounds 
had a dose response value with 50% inhibition less than or equal to 20 µM; 28 of them 
were re-tested from powder samples. After the re-testing, nine compounds with a 50% 
inhibition value of less than 10 µM were further tested for their specificity. Among them, 
only compound 1.21 (Figure 1.5) inhibited Rtt109 without significantly inhibiting 
mammalian p300 or Gcn5.  Its IC50 value is about 56 nM and it inhibited acetylation by 
both Rtt109-Asf1 and Rtt109-Vps75 complexes in similar ways. Kinetic studies showed 
that compound 1.21 reduced Vmax and Km for both AcCoA and the H3 histone peptide. 
Further studies suggested that compound 1.21 is not a competitive inhibitor of either 
AcCoA or the H3 peptide, but a tight or perhaps irreversible inhibitor that displays time-
dependent inhibition against Rtt109. The following structure-activity relationship studies 
illustrated a very narrow SAR for compounds within the same chemical class as 
compound 1.21. Small structural changes of compound 1.21 led to loss of activity or low 
activity. Among the structurally related compounds, only one compound 1.22 displayed a 
poor dose-response and minimal inhibition at the highest concentration tested (1 µM). 
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Figure 1.5. Small molecules as Rtt109 inhibitors 
 
  25 
1.7 Concluding Remarks 
Infectious diseases caused by fungi are presenting a worldwide threat not only to 
animals and plants but also to human health. However, because of the adverse effects, 
drug-drug interactions, and drug resistance, the use of many currently available 
antifungal therapies is restricted. New antifungal treatments that can overcome the listed 
deficiencies are thus desperately needed. 
HATs are enzymes that acetylate histones. They are often involved in the 
regulation of transcription, DNA repair, and other gene regulations. Many HATs have 
been demonstrated to be important drug targets. Among them, Rtt109, a fungal-specific 
histone acetyltransferase, has been shown as a potential antifungal therapeutic target.  
Rtt109 has several unique features. Its catalytic cores, catalytic mechanisms, and 
substrate specificity differ significantly from other HATs. Additionally, the specificity 
and catalytic activity of Rtt109 require an association with one of two histone 
chaperones, Vps75 and Asf1. The availability of Rtt109 X-ray crystal structure enables 
structure-based inhibitor design. However, only a limited number of inhibitors were 
identified even for the whole HAT family. Most of these HAT inhibitors are natural 
products or natural product derivatives including garcinol, curcumin, and Lys-CoA that 
lack selectivity and demonstrate only moderate potency. Thus, there is a critical unmet 
need for potent and selective Rtt109 inhibitors. Further studies on development of novel 
Rtt109 inhibitors as pharmacological tools will shed the light on the understanding of 
roles of Rtt109 in fungal pathogenesis and will also ultimately lead to effective antifungal 
therapeutics for diseases such as candidemia and aspergillosis. 
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CHAPTER 2: 
EXPERIMENTAL HIGH-THROUGHPUT SCREENING 
 FOR INHIBITORS OF RTT109?
2.1 Introduction?
High-throughput screening (HTS) is a widely used technique in the drug 
discovery process. By using automatic systems, HTS allows researchers to quickly 
perform bioassays to provide probe or lead compounds that facilitate scientific research 
and drug discovery.64 Many successful drug-discovery examples that utilize HTS can be 
found in the literature, including the discovery of the anti-HIV drug Maraviroc, a 
chemokine receptor antagonist, eltrombopag, a thrombopoietin receptor agonist, and the 
hepatitis C virus NS5A inhibitors.65 Compared to other approaches such as structure-
based and ligand-based drug design, one advantage of HTS is that the specific structural 
information of the target, mechanism of action, or information on other active compounds 
are not necessary for identifying compounds that modulate biological activity. However, 
there are also several limitations or drawbacks associated with HTS. Usually every 
compound is only tested at a single concentration in the primary screening, which may 
lead to false negatives. Depending on the components used in the bioassay and the 
detection methodology, specific classes of false positives may appear as true actives in 
the initial screening. These false positives need to be identified with counter screens to 
reduce the occurrence of misleading data. Another drawback of HTS is that it costs a 
significant amount of money, which may cause a financial burden in academic settings.  
 In our studies, in vitro HTS was used to identify Rtt109 inhibitors. The issues 
  27 
associated with HTS mentioned above will also be discussed in the following sections. 
 
2.2 Methods and Results 
In vitro Assays. High-throughput screening kinetic assays were performed 
following Trievel et al66 and Chung et al.67 15 nL DMSO or 10 µM test compounds were 
added to wells in Corning 384-well plates (Cat. No. 3677) using an ECHO 550 
contactless liquid handler (Labcyte, Sunnyvale, CA). Controls were added to the 
appropriate wells using the same dispensing method. Next, 5 µL 1X HAT buffer (50mM 
Tris-HCl, 0.1mM EDTA, 50mM KCl, pH 8.0) was added using a Thermo Scientific 
(Rockford, IL) Multidrop 384 bulk reagent liquid dispenser. Following this, the Rtt109-
Vsp75 complex (200 ng/well) and then Asf1-dH3/H4 (800 ng/well) were added using this 
Multidrop dispenser. To initiate the reaction, 10 µL of 15 µM acetyl-coenzyme A was 
added to the entire plate and incubated at 30°C for 1-2 hours. Following incubation, 5 µL 
80 µM 7-diethylamino-3-(4'-maleimidylphenyl)-4-methylcoumarin (CPM, final 
concentration 20µM) that react with the free coenzyme A (CoASH) was added. The 
fluorescence intensity was measured using an M2E plate reader (Molecular Devices) with 
excitation at 405 nm and emission at 530 nm. The assay was validated for top-to-bottom 
and edge-to-edge variability using a control plate where column1 included all 
components (Rtt109-Vsp75, Afs1-H3/H4, AcCoA), column 2 lacked Rtt109-Vsp75, and 
column 3 lacked Afs1-H3/H4. The z-prime values ranged from 0.51-0.67. Finally, the 
HTS protocol was validated using duplicated assay runs of the LOPAC compound 
collection (Sigma-Aldrich, St. Louis, MO) on two separate days. The LOPAC results 
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indicated good reproducibility from day to day and from plate to plate and identified the 
same active compounds in each of the four replicate plates assayed with similar or better 
z-prime values than the control validation plates.  Further details regarding assay 
development are being published under separate cover.68  
Two Production Screenings. Due to the different purposes and priorities in 
different research phases, 82,861 compounds and 142,841 compounds from the 
University of Minnesota in-house “Gopher” (GPHR) compound library were screened 
separately in two production runs. The first HTS (HTS1) was conducted with a detergent-
free buffer. Its aim was to quickly identify potential Rtt109 inhibitors. However, after 
HTS1 was finished, a preliminary analysis of the structural properties of the compounds 
showing apparent inhibition against Rtt109 suggested that potential chemical aggregation 
may lead to the inhibitor-like signals during HTS experiments.69 Thus, based on the 
experience gained in the HTS1, 0.01% Triton X-100 was included in the second HTS 
(HTS2) to reduce the false positives due to non-specific chemical aggregation.70 667 
compounds and 919 compounds were identified as actives from HTS1 and HTS2 
respectively, as they exhibited a percent inhibition greater than three standard deviations 
(3σ) above the mean. These active compounds were cherry-picked for re-testing and 
were evaluated for activity using the same assay and an 8-point, 5-fold dilution dose-
response curve. Known HATs inhibitors garcinol, curcumin, and a curcumin analog 2,6-
bis-(3-bromo-4-hydroxybenzylidene)cyclohexanone served as positive controls while 
fluconazole with no reported activity against HATs was used as a negative control. All of 
the positive controls displayed dose-dependent inhibitory signals in the assays.  An 
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orthogonal antibody-based slot blot assay was then applied to confirm that the inhibitory 
signals corresponded to the true decrease in histone acetylation catalyzed by Rtt109. The 
slot blot assay was performed following standard procedures using a Bio-Rad Bio-Dot SF 
microfiltration apparatus. The resulting membranes were imaged using a LI-COR 
Odyssey andanalyzed using Image Studio (LI-COR Biosciences). Additional control 
experiments were included where only the Rtt109-Vps75 and Asf1-dH3-H4 complexes 
and no AcCoA were added to the plate. Slot blot assays for each compound were 
replicated at least three times by independent experiments. All three positive controls 
exhibited dose-dependent decreases in H3 lysine 56 acetylation in the slot blot assays, 
while fluconazole did not show any detectable decrease in the histone acetylation.  
Interference Assays. To eliminate false positives that produce inhibitory signals 
by reacting with the reagents in the in vitro HTS assay, interference assays were 
developed. The assay conditions and procedures were similar to that in the in vitro HTS 
assay except that no proteins were added to the reaction mixture. The first interference 
assay was designed to test the signal attenuation without proteins. Compounds that do not 
interfere with reagents CPM and CoASH should have similar signals compared to the 
DMSO control. Compounds that interfere with reagents will likely have diminished 
signal relative to the control.  The second interference assay was used to measure the 
fluorescence of the compound itself and detect the formation of fluorescent adducts.  
Compounds that fluoresce themselves under the HTS conditions or produce fluorescent 
adducts with CPM, AcCoA, or CoASH may interfere with the HTS assay and may 
require additional assays to confirm their activities.  
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2.3 Discussion 
The careful design and analysis by our HTS team led to a HTS assay for the 
Rtt109 complex that was more physiologically relevant compared to other reported 
Rtt109 HTS assays. Full-length histone proteins instead of histone peptides were 
incorporated in this assay. Both chaperones Asf1 and Vps75 were also included because 
of their contributions to the catalytic rate and stability of Rtt109.  Thus, our HTS assay 
should reduce the probability of generating misleading data that are due to the use of 
highly artificial and non-physiological assay and would allow the identification of a 
broader spectrum of inhibitors with varying mechanisms of action compared to the 
reported Rtt109 HTS assays. For example, inhibitors identified by our HTS assay can 
directly target Rtt109 or disrupt protein-protein interactions between Rtt109 and Vps75, 
between Rtt109-Vps75 and its substrate histone, or interactions between Asf1 and histone 
H3-H4. Inhibitors may also work by binding to a selection of allosteric sites and thereby 
changing protein conformations affecting histone acetylation. The exact Rtt109 inhibitory 
mechanism has not been definitively established and additional mechanistic experiments 
would be helpful. In addition, HTS assays in general may return false-positives due to 
chemical aggregation, redox activity, and non-specific reactivity. Follow-up experiments 
may be able to triage these false-positives.  
The HTS1 experiments measured Rtt109 activity only and did not correct for false 
positives. However, a clear set of actives and inactives was identified which provided 
training sets for the modeling experiments described below. Although the subsequent 
data from HTS2 differ from those from HTS1, all models were validated internally and 
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models obtained using different techniques agreed well with each other and yielded 
results strongly congruent with the experimentally defined structural features in the 
Rtt109 lysine binding tunnel. These models will be useful to guide the design of small 
molecules targeting the lysine tunnel. 
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CHAPTER 3: 
MOLECULAR DYNAMICS SIMULATION ON RTT109  
?
3.1 Introduction 
 Proteins are in constant motion in physiological environments.71 Experimental 
studies have demonstrated that protein flexibility plays an important role in protein’s 
biological effects, ligand binding, binding orientation, binding kinetics, and so on. Thus, 
understanding the molecular motions of proteins is undoubtedly crucial to drug design. 
However, experiments such as crystallographic and NMR studies that help illustrate 
protein motions are expensive and require extensive labor. Researchers have been 
seeking the relatively cheap computational tools to predict protein dynamics. One of 
these tools is molecular dynamics simulation, which can provide details of the molecular 
motions of proteins as a function of time.72 They use simple approximations based on 
classical mechanics, or more specifically, on Newton’s second equation of motion to 
simulate atomic motions instead of using the complex and computational intensive 
quantum-mechanical level of calculations. With the reduced computational complexity, 
molecular dynamics is able to simulate relatively large protein systems.  
 The force on each atom is determined by the potential energy of the system, U, 
which is the sum of interaction energies, including non-bonded and bonded interaction 
energies.  The non-bonded interaction energies are modeled by van der Waals energy and 
electrostatic energy.73 Van der Waals energy is represented by a combination of the 
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dispersion and repulsion energies and is often modeled by the Lennard-Jones potential as 
written in the following form: 
 
where σAB is the interatomic separation where repulsive and attractive forces balance, rAB 
is the distance between atom A and atom B, and εAB is the Lennard-Jones well depth. 
Both are constants specific to atoms A and B. The electrostatic interaction is represented 
by the Coulomb potential. Each atom is assigned a partial charge, and the interaction 
energy between atom A and atom B is  
 
where εAB is the effective dielectric constant for the medium, rAB is the distance between 
atom A and atom B, qA is the partial charge of atom A, and qB is the partial charge of 
atom B.  
The bonded interaction energies include the bond stretching, valence angle 
bending, and torsion energies. The bond stretching energies are approximated using a 
harmonic potential as in the following form: 
 
where kAB is the bond force constant, which determines the strength of the bond, and  
rAB, eq is the equilibrium bond length. Both kAB and rAB, eq depend on the types of involved 
atoms. The valence angle bending energy is also represented by a harmonic potential: 
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where kABC is the angle force constant and θABC, eq is the angle between three-bonded 
atoms at equilibrium. The torsional potential energy is associated with the steric barriers 
between 1,4-pairs of atoms.  Since torsion is periodic, the torsion potential energy is 
periodic and is modeled by the periodic cosine function: 
 
where kABCD is the dihedral force constant, n is the multiplicity of the function, ωABCD is 
the dihedral angle, and δ is the phase shift. Additional potential energies may include the 
improper dihedral term, which accounts for out of plane bending energy, and the Urey-
Bradley component, which describes angle bending energy using 1,3-nonbonded 
interactions. These energy terms are parameterized based on sophisticated quantum-
mechanical calculations or experimental data in order to represent the behavior of 
molecules. The parameters and the forms of these energy terms are called “force fields”.  
 Currently, MD simulations face two major challenges including the limitations of 
the available force fields and high computational cost. Whenever quantum effects are 
important, MD simulations cannot accurately predict molecular motions. MD methods 
cannot handle the situation of bond breaking and formation and the electronic 
polarization is generally ignored. Although the computational cost of MD has been 
significantly reduced compared to the quantum-mechanical calculations, simulations 
longer than a microsecond are still time consuming and are not conducted routinely. Lack 
of enough simulation time may lead to inadequate conformational sampling and thus key 
events or key conformational state may not be identified.    
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 Although there are several limitations of MD to overcome, MD simulations have 
been contributing to the drug discovery process. MD simulations have played an 
important role in identifying cryptic and druggable allosteric binding sites and in 
predicting free energy of ligand binding.74, 75 MD simulations have also improved the 
identification of true small-molecule binders of enzymes by taking into account the 
receptor flexibility.76 Instead of docking compounds into one X-ray crystal or NMR 
structure, each compound is docked into multiple conformations of the target protein 
generated by MD simulations. This virtual screening protocol better represents the actual 
dynamic ligand binding process and therefore reduces the possibility of missing true 
ligands that are often discarded when using the single experimental structure for virtual 
screening. 
 In this chapter, we reported the results and analysis of the MD simulations on 
Rtt109. The purpose of this MD study is to investigate the flexibility of Rtt109 lysine-
binding tunnel. In addition, multiple conformations of Rtt109 generated by our MD 
simulations may serve as the structures for ensemble docking studies if needed in the 
future.  
 
3.2 Experimental Section 
We performed the MD simulations using the NAMD77 package with the 
CHARMM78, 79 force field for the structure of Rtt109 (2ZFN.pdb31) with explicit water. 
2ZFN.pdb31 was chosen because it was the highest resolution structure available at the 
time the MD experiment was run. Crystallographic water was kept and a truncated 
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octahedral box of TIP3P water was loaded into the system to form the protein 
environment. The system was first energy minimized for 500 conjugate gradient steps. 
The water molecules were then relaxed through a 100 ps simulation with constant 
temperature and pressure and then a 400 ps simulation with constant temperature. The 
temperature and pressure were controlled and maintained at 310 K and 1 atm using the 
Langevin thermostat and Langevin piston barostat control methods. Subsequently the 
whole system was equilibrated for 500 ps under NpT (constant temperature T, pressure p, 
and number of particles N) conditions and 1 ns under NVT (constant temperature T, 
volume V, and number of particles N) conditions. A 10-ns simulation was then 
performed under a constant temperature of 310 K. 
 
3.3 Results and Discussion 
Protein flexibility was assessed by calculating the root mean square deviation 
(RMSD) between the structures generated every 2 ps from the MD simulations and the 
crystal structure. A comparison was then made with the experimental data as a means of 
validation.  
All residues in the simulation were aligned by rigid-body translations and 
rotations and compared to the crystal structure of Rtt109. The average RMSD value of 
residues 1 to 124 and 175 to 404 backbone atoms (excluding missing residues and tail 
residues) compared to the crystal structure of Rtt109 during the 10 ns simulation is 1.40 
Å (Figure 3.1), while the average RMSD of all residue backbone atoms is 3.65 Å. The 
difference between the RMSD values indicates that the flexibility of the tail residues 
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(residues 125 to 142) contributes largely to the RMSD value of all residue backbone 
atoms. The overall average RMSD value of all residue atoms excluding hydrogen atoms 
compared to the starting structure for the 10-ns simulation is 1.81 Å. The RMSD was 
generally stable, indicating the protein was not very flexible. Within the 10-ns simulation, 
no sharp increases in RMSD suggested that no significant conformational changes occur.  
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Figure 3.1. The RMSD value of residues 1 to 124 and 175 to 404 backbone atoms 
compared to the crystal structure of Rtt109 during the 10 ns simulation 
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B-factors in crystallography are assumed to indicate the relative dynamics of 
different parts of the structure. Atoms with low B-factors generally are parts of the 
structure that are well-ordered. Atoms with large B-factors usually indicate that the 
corresponding part of the structure is very flexible.80 In our study, we compared the B-
factor of the Cα atom of each residue (Figure 3.2) and the average RMSD value of the 
Cα atom of each residue (Figure 3.3). We found the general trend for B-factor correlated 
well with that for the calculated RMSD values during the 10-ns MD simulation. As 
shown in Figure 3.2 and Figure 3.3, the residues with peak B-factor values usually have 
peak RMSD values. These residues include residues 40-41, 76, 95-97, 130-132, 175, 251, 
273-274, 299-301, 321-322, 353-355, and 389-391, which have both peak values or close 
to peak values of B factor and RMSD.  These residues are often located at the surface of 
the protein as shown in Figure 3.4. 
The most important area of Rtt109 for our study is the lysine/AcCoA-binding 
tunnel. The residues 65-68, 82-89, 189-200, 213, 215, 218-219, 222, 226, 285-293, and 
323-330 in the lysine-AcCoA binding tunnel were used in our docking studies to 
represent the active site. The average RMSD value of these residues during the 10-ns MD 
simulation compared to the crystal structure was 1.78 Å, which indicated the active site 
was not very flexible. The five residues with the highest RMSD values among the 
residues in the lysine/AcCoA-binding site were Pro286, Asp287, Arg292, Leu323, and 
Ser324, which are listed in Table 3.1 and displayed in Figure 3.5. It is obvious from 
Figure 3.5 that these five residues are also located at the surface of the protein where 
residues are usually more flexible than those that are buried inside the protein.  
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Figure 3.2. The B-factor values for each residue in Rtt109  
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Figure 3.3. The average RMSD of Cα atom of each residue during the 10-ns simulation 
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Figure 3.4. Residues (magenta) with both peak values or close to peak values of B-factor 
and RMSD 
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Table 3.1. The five residues with the highest RMSD values among the residues in the 
lysine/AcCoA-binding site 
Residue ID RMSD (Å) 
Asp287 5.77 
Pro286 4.60 
Ser324 3.95 
Arg292 3.93 
Leu323 3.84 
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Figure 3.5. Five residues (magenta) with the highest RMSD values among the residues in 
the lysine/AcCoA-binding site 
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3.4 Concluding Remarks 
A 10-ns MD simulation was performed on Rtt109 with explicit water at 310K. No 
significant conformational changes were identified during the 10-ns MD simulation 
process. For the 10-ns simulation, the overall average RMSD value of all residue atoms 
excluding hydrogen atoms compared to the equilibrium structure is 1.81 Å. The protein 
dynamics based on the MD simulation showed a trend similar to the experimental B-
values in the X-ray crystallography. Residues 40-41, 76, 95-97, 130-132, 175, 251, 273-
274, 299-301, 321-322, 353-355, and 389-391 have both peak values or close to peak 
values of B factor and RMSD. The most flexible residues reside at the surface of the 
protein, including Pro286, Asp 287, Arg292, Leu323, and Ser324. Overall, the whole 
protein and the lysine/AcCoA-binding site are not very flexible. These results indicate 
that the use of one conformation, the crystal structure of Rtt109, 2ZFN.pdb, for docking 
studies should be appropriate and should not produce large numbers of false negatives.  
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CHAPTER 4: 
VIRTUAL SCREENING STUDIES USING DOCKING AND SCORING  
?
4.1 Introduction 
Docking and scoring is a process that places a molecule (ligand) in the proposed 
binding site of its macromolecular target (receptor) and estimates its binding propensity. 
A successful docking and scoring should be able to accurately (compared to the 
experimental results) predict the binding pose (conformation and orientation) of a ligand 
and its binding affinity.81 Docking and scoring has been widely used in the discovery and 
development of novel drugs. Many successful cases, including the identification of HIV 
protease inhibitors, have shown that the structure-based design via docking and scoring 
heavily influenced the development of drugs.82 When only the target structure is available, 
virtual screening of compound database by docking and scoring usually serves as the 
most applicable computational tool for hit identification. Docking and scoring can also be 
utilized during the lead optimization process. Modifications to known active compounds 
can be prioritized based on the binding affinity predicted by docking and scoring before 
synthesis.  
To identify novel candidate scaffolds for Rtt109 inhibition as well as crucial 
ligand/substrate and receptor interactions, we have used Surflex-Dock23, 83, 84 (Tripos, 
Inc.) and Glide85-87 (Schrödinger, Inc.) to dock small molecule libraries and histone 
substrate mimics. Glide was mainly used to dock the histone substrate mimics into the 
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proper position of Rtt109, because Glide has the functionality to dock compounds with 
user-defined constraints that facilitates the docking of the flexible peptides. 
4.1.1 Surflex-Dock 
The Surflex-Dock utilizes the fragmentation and similarity search techniques.84 
An idealized active site ligand (protomol), which complements the receptor active site, is 
first generated as a template for computing putative binding poses of a molecule or a 
molecular fragment. To generate the protomol, three types of molecular probes are placed 
into the receptor active site. The molecular probes include CH4 as a steric (hydrophobic) 
probe, C=O as a hydrogen-bond acceptor probe, and N-H as a hydrogen-bond donor 
probe. Each probe’s position and orientation are optimized based on the scoring function, 
in order to maximize its interaction with all protein atoms.88 Low-scoring, isolated, and 
redundant probes are eliminated. The remaining probes collectively constitute the 
protomol. 
The second step involves the molecular fragmentation.84 To reduce the 
computational time in conformational sampling, each molecule is fragmented by 
breaking its non-ring rotatable bonds. To achieve molecular flexibility of ligands in 
docking, a heuristic set of rules are applied to the conformational sampling, where two, 
three, or six rotamers are used for each bond. In addition, the algorithm picks the most 
different conformations per fragment based on the root-mean-square deviation. The user 
can specify the maximum number of conformations per fragment.  
 The third step is to align the fragments and construct the full molecules.84 All 
conformations of all molecular fragments are aligned with the “protomol” based on 
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similarity. The aligned fragments are scored and pruned according to the scoring 
function. Then using a “Hammerhead” approach, the conformations of full molecules are 
constructed from the aligned fragments.89 The best scoring poses (conformations) are 
optimized and returned with their scores. 
Surflex-Dock uses an empirically derived scoring function that is based on the 
binding affinities of experimentally determined protein-ligand complexes, with its output 
scores expressed in -log10(Kd) units as the estimated binding affinities.90 The scoring 
function is a weighted sum of non-linear functions, including the following terms: 
1) Hydrophobic: a weighted sum of a Gaussian-like function and a sigmoid 
function over all atom pairs, which captures the positive atomic contact and the negative 
atomic contact due to atomic interpenetration. 
2) Polar: a sum over all pairs of complementary polar atoms to represent the 
effects of hydrogen bonds and salt bridges.  
3) Entropic: a penalty term that is linearly related to the number of rotatable bonds 
in the ligand and to the log of the molecular weight of the ligand, intending to model the 
loss of translational and rotational entropy of the ligand once the ligand is docked.  
4) Solvation: a term that is linearly related to a count of the difference between 
the potential and actual numbers of hydrogen bond equivalents. 
4.1.2 Glide 
In Glide, the shape and other properties of the receptor are computed and 
represented on a grid by binned site points and receptor distances before the docking 
process.87 In the next step, an exhaustive conformational and position search of the ligand 
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over the active site of the receptor is conducted, followed by a heuristic screen that 
eliminates high-energy conformations and other unsuitable binding conformations.  The 
remaining conformations of the ligand are minimized within the receptor using a 
molecular mechanics energy function of the OPLS-AA force field.91 After that, three to 
six lowest-energy poses are subjected to a Monte Carlo process that explores nearby 
torsional minima. An extended and modified version of the ChemScore92 funcion, 
GlideScore is utilized to predict binding affinity and rank ligands in the database virtual 
screens. The GlideScore function includes a lipophilic-lipophilic term, three differently 
weighted hydrogen-bonding terms, a metal-ligand interaction term, a polar-hydrophobic 
term, terms for the Coulomb and vdW interaction contributions, and terms to deal with 
the solvation effects. However, Glide uses the Emodel function which has a more 
significant weighting of electrostatic and van der Waals energies to select the docked 
pose.  
 
4.2 Experimental Section 
To identify potential scaffolds for inhibitor design, I screened approximately 7 
million non-redundant compounds in silico for potential activity against Rtt109. These 
structures were obtained from five small-molecule databases: DrugBank93, LeadQuest94, 
the University of Minnesota in-house “Gopher” (GPHR) library, the University of 
Minnesota Institute for Therapeutics Discovery and Development (ITDD) compound 
database, and a novel peptoid (poly-N-substituted glycines) probe library generated by 
the Walters laboratory. All compound databases were first refined using a set of three 
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filters in the SciTegic PipelinePilot data analysis and reporting platform (Accelrys, 
Inc.)95, retaining only those structures that satisfied Lipinski’s Rule of Five96, and did not 
contain inorganic atoms and/or reactive substructures. Predicted bound configurations for 
these structures were obtained using Surflex-Dock (SYBYL 8.0, Tripos, Inc.), with 
2ZFN.pdb31 representing the Rtt109/AcCoA binary structure.  The protomol (active-site 
representation) corresponded to residues 65-68, 82-89, 189-200, 213, 215, 218-219, 222, 
226, 285-293, and 323-330 in the Lys-AcCoA binding tunnel.  Docked poses were 
ranked by total Surflex-Dock score expressed as –log(Kd). Threshold and bloat 
parameters were set to 0.5 and 0, respectively.  The maximum number of conformations 
per compound fragment and the maximum number of poses per molecule were both set to 
twenty, and the maximum allowable number of rotatable bonds per structure was limited 
to 100.  Post-dock minimizations were carried out on each ligand to optimize predicted 
configurations in the receptor site. 
To identify potential substrate and receptor interactions, several peptide pieces 
were docked into the Rtt109 lysine binding area using Glide. These peptides contained 
the lysine residue that was acetylated by Rtt109 and its neighbor residues on the histone 
tail to mimic the substrate. Using 2ZFN.pdb31 with AcCoA removed, a Glide grid was 
computed with an outer box region of 20 Å to represent the receptor. The grid midpoint 
was defined by the centroid of the lysine entrance tunnel that was composed of residues 
65-68, 82-89, 189-200, 213, 215, 218-219, 222, 226, 285-293, and 323-330. 
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4.3 Results and Discussion 
Compounds were retained which exhibited a Surflex-Dock score of 10 or greater, 
corresponding to predicted Kd values of 0.1 nM or lower, resulting in 961 potential hits. 
This virtual screening process has yielded 6 DrugBank, 32 LeadQuest, 83 GPHR, 747 
ITDD, and 93 peptoid compounds (Table 4.1). The five highest-scoring compounds from 
the overall screening process are shown in Table 4.2 together with corresponding 
Surflex-Dock scores. Figure 4.1 illustrates the docked configurations of these compounds 
along with key ligand-receptor interactions predicted by the docking. These compounds 
share some common features: a linear scaffold which fits well with the narrow lysine 
binding tunnel and several polar functional groups on the scaffold which make H-
bonding or Coulombic interactions with residues inside the lysine tunnel. The highest 
scoring compound, 4.1 (Total Score = 12.43), was predicted to donate a H-bond to the 
backbone CO of Asp287 as shown in 2D and 3D interaction maps (Figure 4.2 and Figure 
4.3). Its propyl group fits within the small hydrophobic area formed between Phe84 and 
Leu191. The oxygen atoms on the sulfonamide group point to the solvent-exposed area 
and make favorable Coulombic interactions with the polar residues at the entrance of the 
lysine tunnel. The phenyl ring can π-π interact with the Tyr199 side chain while having 
hydrophobic interactions with other nearby hydrophobic residues. The Trp222 side chain 
and the Leu213 backbone were predicted to donate a H-bond to the CO and ether O 
atoms of compound 4.1, respectively. Favorable hydrophobic interactions can be formed 
between the 1,2-dimethoxybenzyl group of compound 4.1 and the residues Phe62, Ile212, 
and Leu213.  
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Table 4.1. Virtual screening results 
database # of cpds in 
database 
# of cpds scoring 
10 or higher 
preliminary 
hit rate (%) 
DrugBank 4406 6 0.14  
LeadQuest 53640 32 0.06  
GPHR 208593 83 0.04  
ITDD  1050000 747 0.07  
Peptoids 11046 93 0.84  
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Table 4.2. Five highest-scoring compound structures from among all compounds 
screened to date, with total Surflex-Dock scores 
 
Structures Compound ID Total Score 
 
 
4.1 
 
12.43 
 
4.2 12.41 
 
4.3 12.32 
 
4.4 12.28 
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4.5 12.25 
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Figure 4.1. Three-dimensional renderings of five highest-scoring compounds (hydrogens 
undisplayed) docked into Rtt109 (2ZFN.pdb31) (SYBYL 8.0, Tripos, Inc.) 
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Figure 4.2. Two-dimensional interaction map of compound 4.1 with Rtt109 (MOE 
2010.10, Chemical Computing Group, Inc.) 
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Figure 4.3. Three-dimensional interaction map of compound 4.1 with Rtt109 (SYBYL 
8.0, Tripos, Inc.) 
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To better understand the potentially important interactions between compounds 
and the lysine tunnel, we analyzed the residues that were frequently involved in the 
interactions between the protein and the top scoring compounds from different databases 
in our docking studies. These residues include Pro286, Ser86, Arg292, Arg194, Asp288, 
Asp287, Trp222, Val85, Ala88, Phe192, Lys87, Ala196, and Tyr199. The details of the 
frequency and the type of interactions of these residues are shown in Table 4.3. 
Interestingly, single-site mutagenesis studies have shown that residues Tyr199, Trp222, 
Asp287 and Asp288 are important for the catalysis and/or substrate binding of Rtt109 
and these four residues are also predicted to be key residues that interact with the 
compounds in the lysine-binding tunnel.31, 38, 44 Thus these residues may be most 
important residues to target when designing Rtt109 inhibitors.  
Twenty-two commercially available compounds (see Table 4.4) with highest 
scores were experimentally examined for their inhibitory activities against Rtt109 using 
the HTS2 method described in Chapter 2. None of them showed activity at the 
concentration of 250 µM. It is possible that minor side chain movements in the narrow 
active site may impact on the prediction of affinity and pose of compounds. Although 
molecular dynamics simulations can be applied to capture some of these movements, it is 
very difficult to identify the important but subtle side chain movements that will actually 
contribute to compound binding from millions of the snapshots generated by the 
molecular dynamics simulations. In addition, very little experimental data were available 
to allow us to conduct the benchmark work. It is also possible that the sampling of ligand 
conformations did not capture the ligand-binding conformation among all docking poses. 
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The scoring function was also not guaranteed to linearly rank compounds according to 
their inhibitory activities. The solvation energy and the associated entropy penalty for 
ligand binding may not be taken fully into account in the scoring functions. Therefore, for 
our highest scoring compounds that contain many polar groups, this inaccurate estimation 
may lead to relatively larger errors compared to those of compounds that contain fewer 
polar groups.  
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Table 4.3. Key residues that are predicted to interact with the ligands (A: H-bonding 
acceptor; D: H-bonding donor; π+: π-cation interactions; π π: π-π interactions) 
 
Residues 
Frequency Count 
(top 22 ligands from 
peptoids) 
Frequency Count 
(top 30 ligands from 
GPHR) 
Frequency Count 
(top 12 from ITDD 
vendor database) 
Pro286 (A) 16 2 0 
Ser86 (A) 15 1 0 
Arg292 (D) 13 5 5 
Arg194 (D) 13 6 6 
Asp288 (A) 12 3 1 
Asp287(A) 10 9 3 
Trp222 (D)/(π+) 10 15 5 
Val85 (A) 7 2 0 
Ala88 (A)/(D) 7 22 6 
Phe192 (A) 5 3 2 
Lys87 (π+)/(D) 5 1 0 
Ala196 (D) 4 3 1 
Tyr199 (π π) 1 23 5 
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Table 4.4. Twenty-two commercially available compounds that were experimentally 
examined for their inhibitory activities against Rtt109 using the HTS2 method described 
in Chapter 2 
 
Structures Total Score 
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In the docking studies of the peptide substrate mimics, the tripeptide Q-K-S with 
N-terminal acetyl and C-terminal amide capping groups was first docked into the Rtt109 
lysine entrance tunnel. The lysine tail of the tripeptide goes into the lysine entrance 
tunnel as the Rtt109 mechanism suggests and has a hydrogen-bonding interaction with 
Ser86 of Rtt109. The Gln and Ser moieties of the tripeptide is proposed to interact with 
residues Tyr199, Lys87, Asp287, Gln198, and Arg194 near the surface or on the surface 
of Rtt109 as shown in Figure 4.4. A pentapeptide Y-Q-K-S-T was then docked using the 
same method with one constraint, that the lysine side chain of the pentapeptide and 
Rtt109 residue Ser86 need to form a hydrogen bond. This constraint was added in order 
to make sure the lysine portion of the pentapeptide dock into the lysine entrance tunnel 
instead of the surface of Rtt109. Figures 4.5 and 4.6 illustrate the detailed interactions 
between the pentapeptide and Rtt109. Residues Ser86, Asp287, Lys87, and Arg292 
interact with the pentapeptide. These residues may play important roles for the histone 
binding and guide the design of inhibitors that block the protein-protein interaction 
between Rtt109 and histone. 
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Figure 4.4. Two-dimensional interaction map of the tripeptide with Rtt109 (MOE 
2010.10, Chemical Computing Group, Inc.) 
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Figure 4.5. Two-dimensional interaction map of the pentapeptide with Rtt109 (MOE 
2010.10, Chemical Computing Group, Inc.) 
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Figure 4.6. Three-dimensional interaction map of the pentapeptide with Rtt109 (SYBYL 
8.0, Tripos, Inc.)?
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4.4 Concluding Remarks 
Understanding the structural bases for molecular recognition between an enzyme 
protein and its inhibitors is important for the identification of new inhibitors and the 
optimization of known inhibitors. Structural biology experiments such as X-ray 
crystallographic and NMR studies play key roles in helping researchers understand these 
structural bases. Docking and scoring studies take advantage of the structural information 
and aid the rational drug design. In our studies, we utilized docking and scoring as a 
virtual screening tool in order to identify novel inhibitors against Rtt109. By analyzing 
the predicted key ligand-receptor interactions, we found that residues Pro286, Ser86, 
Arg292, Arg194, Asp288, Asp287, Trp222, Val85, Ala88, Phe192, Lys87, Ala196, and 
Tyr199 may be the key residues that contribute to the ligand binding. Among them, 
residues Tyr199, Trp222, Asp287 and Asp288 have been demonstrated experimentally to 
be important for the catalysis and/or substrate binding of Rtt109 and thus they should be 
the most important residues to target for designing Rtt109 inhibitors. We also explored 
the potential interactions between the substrate histone and Rtt109 on the surface between 
these two proteins by docking truncated peptide fragments of histone. Ser86, Asp287, 
Lys87, and Arg292 of Rtt109 are predicted to be major residues that interact with histone. 
These residues may also need to be targeted by Rtt109 inhibitors in order to efficiently 
interrupt the interactions between Rtt109 and histone. Twenty-two highest scoring 
compounds were tested against Rtt109 using the HTS2 assay method but demonstrated 
negligible activities experimentally. The reasons for these results may be: 1) the fact that 
subtle side chain movements may make major differences in the structure of a small and 
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narrow tunnel, and 2) the limitations of the docking and scoring on our protein system. 
The X-ray crystallographic studies are ongoing. With further information from the 
structural biology studies, we will refine and improve our docking and scoring studies in 
the future.  
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CHAPTER 5: 
THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY 
RELATIONSHIP STUDIES ON Rtt109 INHIBITORS 
 
5.1 Introduction 
Three-dimensional quantitative structure-activity relationship (3D-QSAR) is a 
method for building a statistical model which correlates biological activities of 
compounds with their three-dimensional structural properties. Based on the assumption 
that receptor-ligand interactions are shape- and structure-dependent, 3D-QSAR methods 
can be employed to elucidate binding characteristics, predict biological activities of novel 
structurally similar compounds, and improve the potency of known inhibitors.41, 97 3D-
QSAR is a “ligand-based” technique that requires no initial active-site structural 
information and is particularly effective in cases when the targeted receptor is unknown 
or difficult to model, or, in the case of Rtt109 inhibitor design, when the target is known 
but the active-site location is uncertain.98 
There are usually several additional assumptions in 3D-QSAR methods, including 
the following: 
1) All compounds in training series interact with the same binding site on the 
same receptor in the same manner. 
2) Interactions that lead to biological effects are non-covalent and mainly 
enthalpic. 
3) The entropic cost upon the binding of compounds in training series follows a 
similar pattern. 
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4) The biological activities are caused by the ligands themselves and not by their 
metabolites or degraded portions.  
Thus, in order to build reliable 3D-QSAR models, the selected compounds as the 
training set need to satisfy the requirements above.  
 
5.1.1 CoMFA and CoMSIA 
Comparative Molecular Field Analysis (CoMFA99) and Comparative Molecular 
Similarity Indices Analysis (CoMSIA100) are two commonly used 3D-QSAR methods. In 
CoMFA, all molecules in the training set are aligned using manual or automated 
methods. Ligand molecules are represented by their steric and electrostatic fields.99 To 
calculate the steric and electrostatic fields, the ligand molecules are placed in a three-
dimensional lattice grid that is large enough to cover all molecules in this series. A 2.0-Å 
separation between lattice points is chosen to make the computation efficient. A probe 
atom with the van der Waals properties of an sp3 carbon atom and a charge of +1.0 is 
placed at the intersections of the lattice. The energies of steric interaction between a 
ligand and a probe atom are calculated using Lennard-Jones 6-12 potential with 
parameters from the standard Tripos force field.101 The energies of electrostatic 
interaction between a ligand and a probe atom are calculated based on the Coulomb 
potential function, and the atomic charges are calculated using a method of the user’s 
choice. Both the Lennard-Jones 6-12 potential and Coulomb potential curves are very 
steep when the distance is close to the van der Waals surface. In addition, the Lennard-
Jones and Coulomb potentials demonstrate singularities at atomic positions. Thus, cutoff 
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values (30 kcal/mol by default) are used to avoid unacceptably large values and dramatic 
changes in surface descriptions. These interaction energy or field values and the ligands’ 
biological activity values constitute a data table with many more columns than rows. The 
partial least-squares (PLS) technique is then used to correlate the field values with the 
biological activity data. The PLS analysis resembles the principal component regression 
analysis and has the advantages of deriving robust linear regression equations from tables 
with many more columns than rows (more independent variables than samples). A certain 
percentage (e.g., 5%) of the increase of the cross-validated rcv2 serves as a criterion to 
extract only significant components because too many components will lead to an 
overfitting of the model. The cross-validation evaluates the internal predictivity of a 
CoMFA model and also determines the optimum number of the PLS components. The 
PLS regression analysis is then applied without cross-validation using the optimum 
number of components, resulting in the final models from which conventional correlation 
coefficient r2, its standard errors, and F ratios (ratios of r2 to 1-r2) are calculated. 
Comparisons between the predicted and experimental activities are made to identify 
potential outliers (observation points distant from the majority). The outliers may be 
removed from the training set to yield a better model with an improved rcv2, r2, and F 
ratio. Because of the thousands of coefficients in the regression equation, a direct 
interpretation of the equation is difficult and not very useful. Instead, the result of the 
analysis is presented by three-dimensional contour maps. These maps are generated using 
the products of the coefficients and standard deviation and indicate lattice points or areas 
where changes in CoMFA field values strongly associate with changes in biological 
  75 
activities.  
As discussed above, there are problems with the CoMFA method.  Both Lennard-
Jones and Coulomb potential functions are very steep near the van der Waals surface of 
the ligand, requiring the use of cut-off values. In addition, entropic contributions to the 
binding affinities or biological activities are neglected in CoMFA. To overcome these 
problems, an alternative method CoMSIA100 was developed by Klebe and co-workers. 
This approach computes ligands’ property fields based on similarity indices of aligned 
molecules. The similarity is not measured directly by comparing all pairs of molecules. 
Instead, the similarity is represented by the similarity of each molecule with probe atoms 
placed at grid lattice points. Gaussian-type functions are selected to calculate the distance 
dependent similarity indices and to represent different physicochemical properties. 
Because Gaussian-type functional forms are smooth without singularities, no arbitrary 
cut-off values are needed. A general CoMSIA procedure is similar to the standard 
CoMFA approach.  A default grid spacing of 1 Å is used (as described in the literature). 
Similarity indices AF, k between the ligands (j) and a probe atom (at grid point q) are 
calculated according to the following equation100: 
 
where i is the summation index over all atoms of the molecule j; ωprobe, k is the probe atom 
with a radius of 1 Å, a charge of +1, a hydrophobicity of +1, a hydrogen bond donating of 
+1, and a hydrogen bond accepting of +1; ωik is the actual value of the property k of atom 
i; riq is the distance between probe atom at the grid point q and atom i of the molecule; 
and α is the attenuation factor, with a default value of 0.3. The default value is chosen 
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because a larger α will lead to an increasing attenuation of distance-dependent effects of 
molecular similarity and global molecular features become less significant. The data table 
is then constructed from the calculated similarity indices and then the PLS technique is 
applied to extract a QSAR relationship from the data table. Although CoMSIA also 
encounters some of the limitations of CoMFA, it has the following obvious advantages: 
1) The probes are not limited to steric or electrostatic fields but also include other 
fields including hydrophobic and hydrogen bonding, which describe more 
physicochemical properties compared to CoMFA. 
2) The entropic effect in the form of hydrophobic interactions can be taken into 
account at least partially by using hydrophobic probes.41 
3) CoMSIA contour maps denote the regions occupied by the ligand that favor or 
disfavor a particular physicochemical property, which provide a more direct visual guide 
for modification of the ligand.  
 In our studies, we have applied both CoMFA and CoMSIA to build 3D-QSAR 
models that illustrate the correlations between specific changes in Rtt109 inhibitor 
structures and their biological activities. We also expect that information gained from 
these models will guide the modifications of Rtt109 inhibitors.  
 
5.2 Experimental Section 
5.2.1 3D-QSAR Modeling 
Initial CoMFA and CoMSIA models were developed using a 115-compound 
training set (17 actives and 98 inactives from HTS1) comprising all thiourea-based 
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structures in our in-house compound collection.  In vitro Rtt109 IC50 values for these 
seventeen actives ranged from 1.73 µM to 11.46 µM according to the HTS1 results. 
Because molecules with activities spanning about two to three log units are needed to 
build a statistically sound and reliable model, inactives were included in the training set 
and were assigned IC50 values of 1000 µM.98 3D configurations of all 115 structures were 
generated using geometry optimization by energy minimization in Pipeline Pilot 8.0. 
Datasets were aligned in SYBYL-x/1.0 using the optimized structure of the most active 
compound in the training set (5.1, GPHR-00029275, Table 5.1) as the template 
molecule102 and applying a rigid alignment method based on common substructures.  
Gasteiger-Hückel103, 104, Gasteiger-Marsili,103 MMFF94,105 and Hückel104 charges were 
calculated for all structures. Subsequent removal of outliers decreased the number of 
active compounds in the training set to 14, and the overall compound count to 93. 
Following standard CoMFA and CoMSIA procedures, each compound was placed into a 
three-dimensional lattice with a 2.0 Å grid-point separation. For CoMFA, the steric (van 
der Waals) and electrostatic (Coulombic) potential energy fields were obtained by 
summing individual energy interactions between each atom of the compound of interest 
and an sp3 carbon probe atom with a charge of +1, located at each grid point. A distance-
dependent dielectric function (ε = ε0 r, where ε0 = 1) was applied, and maximum field 
values were set to 30 kcal/mol for the steric fields and to ±30 kcal/mol for the 
electrostatic fields. For CoMSIA, similarity indices were computed using an sp3 carbon 
with a charge of +1, radius of +1 Å, hydrophobicity of +1, and hydrogen-bond donor and 
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acceptor properties of +1; the attenuation factor α for the Gaussian-type distance 
dependence was set to 0.3. 
5.2.2 QSAR Regression Analysis 
Linear regression equations in QSAR modeling were derived using the partial 
least squares (PLS) methodology,106 in which changes in steric and electrostatic fields 
(CoMFA) and five similarity fields (CoMSIA) were correlated with changes in 
experimental biological activities (pIC50 values) in the training set. The internal 
predictive ability of the models was first evaluated by “leave-one-out” cross-validation, 
whereby each compound was removed from the training set, and a new model was 
derived using the remaining compounds and subsequently used to predict the activity of 
each extracted compound, yielding the optimum number of principal components (PC) in 
the linear equation and a cross-validated r2 (rcv2) value, which is a statistical 
representation of internal predictivity. The PLS calculations were then repeated, without 
cross-validation, using the optimum number of PCs, resulting in final CoMFA and 
CoMSIA models with corresponding conventional r2 values, standard errors of estimate, 
F ratios, and other related statistical parameters. Column filtering was applied to any 
column of computed energies with a variation less than 2.0 kcal/mol, in order to 
accelerate the regression analysis and to reduce “noise.” Each 3D-QSAR model was 
visualized as a color contour map illustrating regions of descriptor fields that strongly 
contributed to the overall model. 
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5.3 Results and Discussion 
5.3.1. 3D-QSAR Modeling 
To correlate specific changes in Rtt109 inhibitor structure with biological 
activities, we generated a series of 3D-QSAR models based on a selection of active and 
inactive compounds from our HTS1 assay, using CoMFA and CoMSIA.  Based on the 
assumption that enzyme-inhibitor interactions are largely noncovalent, enthalpic, and 
shape-dependent, these industry-standard methods derive 3D-QSAR models by 
systematically sampling steric and electrostatic fields surrounding a set of small 
molecules (CoMFA) or calculating Gaussian-function similarity indices representing 
steric, electrostatic, hydrophobic, and hydrogen bonding interactions (CoMSIA) and 
correlating the respective fields with experimental biological activities. Both techniques 
yield visual representations of areas on the ligands where the respective properties 
correlate strongly with increases or decreases in biological activity, as well as 
quantitative models that, if statistically sound, can be used to predict the activities of 
structurally similar compounds.  The predictivity and reliability of the CoMFA and 
CoMSIA models were assessed by means of four primary parameters: conventional r2, a 
measure of how well predicted biological activities for the training set compounds agree 
with experimentally determined values; cross-validated r2 (rcv2, from a “leave-one-out” 
cross-validation procedure, see 5.2 Experimental Section); F-ratio (defined as r2/(1-r2) 
and representing the ratio of properties explained by the QSAR model to those not 
explained by it102); and standard error of estimate, or SEE. After extensive generation and 
testing of 3D-QSAR models (not reported here) from combinations of various active and 
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inactive compound subsets, and applying a variety of charge formalisms, a training set 
was chosen that comprised all compounds in the entire 82,861 in-house compound 
collection that featured a thiourea core structure (17 actives and 98 inactives), with 
Gasteiger-Hückel charges.103, 104 Using this 115-compound thiourea-based set, compound 
5.1 (GPHR-00029275, Table 5.1) as the template for molecule alignment, and a QSAR 
column filtering level of 1.0 kcal/mol, a preliminary CoMFA model was developed that 
exhibited very good internal predictive ability (rcv2 = 0.712), good self-consistency (r2 = 
0.938), and a favorable F-ratio (271.225), but also a rather high SEE (0.221). Twenty-two 
“outlier” compounds (three actives and nineteen inactives) were removed that exhibited 
residual differences in predicted vs. experimental biological activity greater than or equal 
to 0.2 log units, resulting in a final training set comprising 14 actives (Table 3) and 79 
inactives.  (Note that all inactive compounds demonstrated zero activity against Rtt109 
and were consequently assigned numerical pIC50 values of 3.0 for the purposes of this 
QSAR analysis – which also enabled the resulting models to distinguish sharply between 
actives and inactives, given that the training set actives exhibited a rather narrow activity 
range (1.73 – 11.46 µM) and models based on the training set actives only displayed less 
satisfactory statistical results). The new CoMFA model derived from this final compound 
set displayed a slight increase in internal predictivity (rcv2 = 0.751), better self-
consistency (r2 = 0.985), a significantly higher F-ratio (970.516), and, notably, a 
decreased standard error of estimate (0.107) (Figure 5.1). The best CoMSIA model 
obtained using this final training set did not prove as self-consistent as the respective 
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CoMFA model, but was internally predictive as determined by cross-validation (rcv2 = 
0.651, r2 = 0.977, SEE = 0.135, and F = 601.876, Figure 5.2). 
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Table 5.1. Fourteen active, thiourea-based Rtt109 inhibitors from the final 3D-QSAR 
compound training set, with Rtt109 pIC50 and IC50 values 
Cpd 
# 
Structure Cpd ID Rtt109 
pIC50 
Rtt109 
IC50 (µM) 
5.1  
 
GPHR-
00029275 
5.76 1.73 ± 0.46 
5.2 
 
 
GPHR-
00026554 
5.69 2.01 ± 0.35 
5.3  
 
GPHR-
00006279 
5.53 2.96 ± 0.68 
5.4 
 
 
GPHR-
00022505 
5.49 3.22 ± 0.84 
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5.5 
 
 
GPHR-
00053162 
5.49 3.26 ± 0.60 
5.6 
 
 
GPHR-
00023078 
5.41 3.89 ± 1.49 
5.7 
 
 
GPHR-
00053677 
5.36 5.4 ± 1.30 
5.8  
 
GPHR-
00011814 
5.32 5.82 ± 1.38 
5.9 
 
 
GPHR-
00029320 
5.29 5.04 ± 2.09 
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5.10  
 
GPHR-
00029429 
5.28 5.30 ± 2.14 
5.11  
 
GPHR-
00058009 
5.27 5.32 ± 2.09 
5.12  
 
GPHR-
00029520 
5.19 6.36 ± 2.34 
5.13 
 
GPHR-
00031245 
5.15 7.13 ± 2.30 
5.14  
 
GPHR-
00029708 
4.94 11.46 ± 
3.55 
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Figure 5.1. Plot of the CoMFA-predicted vs experimental biological activities for the 
final thiourea-based Rtt109 inhibitor training set.  All inactive compounds were assigned 
an experimental pIC50 value of 3.0.   
 
 
 
 
r2 = 0.985 
rcv2 = 0.751  
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Figure 5.2. Plot of the CoMSIA-predicted vs experimental biological activities for the 
final thiourea-based Rtt109 inhibitor training set. All inactive compounds were assigned 
an experimental pIC50 value of 3.0.  
 
 
r2 = 0.977 
rcv2 = 0.651  
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5.3.2 Model Interpretation 
The color contour map of the most predictive CoMFA model is shown in 
Figure 5.3, together with the docked configuration of compound 5.1, superimposed on the 
MOLCAD107, 108 fast Connolly electron-density surface of the Rtt109 Lys-AcCoA 
binding tunnel, with electrostatic potential mapping. All training set active compounds 
were docked using the same method and displayed similar docking poses compared to the 
docking pose of compound 5.1. Green polyhedra indicate regions on the inhibitor where 
steric bulk is predicted to favor biological activity against Rtt109, whereas yellow 
polyhedra denote areas where ligand bulk is likely to decrease activity. Similarly, blue 
and red areas represent, respectively, inhibitor areas where positive and negative 
electrostatic potential correlate with increased activity. A broad green region located 
adjacent to the p-chlorophenyl moiety in 5.1 suggests a tolerance for steric bulk at the 
AcCoA binding region of the tunnel. Yellow polyhedra located nearby highlight steric 
constraints that come into play as the tunnel narrows. Favorable steric potential as 
denoted by a green area near the o-carboxylphenyl grouping appears to conflict with 
corresponding structural features in the receptor. However, it more accurately reflects the 
variety of bound configurations possible at the entrance to the Lys tunnel rather than a 
need for bulky groups to be added to the ligand in this area.  A strong preference for 
electronegative groups near the carboxylic acid moiety on 5.1 (red polyhedra) is 
consistent with the observation from our in vitro HTS1 data that negatively charged 
functionalities on one or more of the ligand aromatic moieties generally correlate with an 
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increase in Rtt109 inhibition. Two smaller blue regions near the hydrogen atoms of the o-
carboxyphenyl moiety point to a preference for electropositive groups in these areas. 
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Figure 5.3. CoMFA contour map (SYBYL-x/1.0, Tripos, Inc.) for the final thiourea-
based Rtt109 inhibitor training set, shown with compound 5.1 (Rtt109 pIC50 = 5.762, IC50 
= 1.73 µM) and the MOLCAD electron-density surface of the Rtt109 Lys-Ac-CoA 
binding tunnel, with electrostatic potential mapping on the receptor (red = positive; violet 
= negative). Colored polyhedra represent areas on or near the ligand where properties 
correlate strongly with biological activities, where red = negative electrostatic potential; 
blue = positive electrostatic potential; yellow = negative steric potential; green = positive 
steric potential.  
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Figure 5.4 illustrates the corresponding CoMSIA model, shown with compound 
5.1 and the MOLCAD107, 108 Rtt109 binding tunnel electron density surface with 
electrostatic (Figure 5.4a), hydrogen-bonding (Figure 5.4b) and lipophilic (Figure 5.4c) 
potential mapping. The CoMSIA steric and electrostatic fields agree well with those 
obtained by CoMFA, and the additional hydrogen-bond donor, hydrogen-bond acceptor 
and hydrophobic contour maps provide supplemental information regarding small-
molecule binding requirements in the Rtt109 Lys tunnel. In Figure 5.4b, a cyan area 
located proximal to thiourea amino groupings on the ligand and near the backbone 
carbonyl of Arg194 on the receptor indicates that a hydrogen-bond donor in this position 
will correlate with an increase in biological activity. A corresponding magenta 
polyhedron (H-bond acceptors favored) in the vicinity of the ligand carboxylic acid 
points to a key hydrogen bonding interaction between that carbonyl and one of the 
Arg194 side chain amino moieties, as well as between the Thr193 backbone amino 
grouping and the carboxyl OH of the inhibitor. Interestingly, the CoMSIA fields 
represent proportionally more disfavored interactions in this case than the CoMFA maps, 
perhaps due to five fields (rather than two) being calculated for the relatively large 
number of inactive compounds in the training set. For example, in Figure 5.4b, the large 
purple area on the lower left-hand side overlaps with a yellow polygon, underscoring a 
correlation between hydrogen-bond donors, steric bulk, and decreased biological activity 
in this region. In addition, a low tolerance for hydrogen-bond acceptors on the ligand near 
the Rtt109 Pro297 side chain is denoted by the orange polygon on the upper left-hand 
side of the diagram, while the nearby (and slightly overlapping) purple area indicates that 
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hydrogen-bond donors are also disfavored at this region – both of which, taken together, 
correspond with structural biology data that hydrogen bonding of any kind is not likely to 
take place in this part of the tunnel. Another orange region near the lower left-hand side 
of compound 5.1, flanked by the large purple area, indicates that hydrogen-bond 
acceptors are disfavored on the ligand near the aliphatic part of Lys87, which is further 
consistent with experimental structural data as no hydrogen-bond donors within an 
acceptable distance are present on the receptor.   
The hydrophobic contour map of the best CoMSIA model (Figure 5.4c) correlates 
very well with hydrophobic features in the putative Rtt109 small-molecule binding site.  
The hydrophobic part of the Lys-AcCoA tunnel formed by residues Lys210, Ile212, and 
Trp221 is correctly reflected by the two brown polyhedra in the contour map. A gray area 
near the upper right-hand of the molecule suggests that hydrophobicity may be disfavored 
at that location, but viewing the hydrophobic and steric similarity indices simultaneously 
reveals an overlap between this gray polygon and an area where steric bulk is strongly 
disfavored, meaning that no substituents of any kind are allowed in that region, 
hydrophobic or otherwise. However, the gray polyhedron on the ligand near the solvent-
exposed entrance to the tunnel (lower left side of the illustration) correlates with the more 
hydrophilic environment in this area.  Good agreement was observed between all features 
in the best CoMFA and CoMSIA models and steric, electrostatic, hydrophobic and 
hydrogen-bonding requirements in the Rtt109 Lys tunnel as determined by experiment.  
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Figure 5.4. CoMSIA contour maps (SYBYL-x/1.0, Tripos, Inc.) for the final thiourea-
based Rtt109 inhibitor training set, shown with predicted bound configuration of 
compound 5.1 (Rtt109 pIC50 = 5.762, IC50 = 1.73 µM) and the MOLCAD electron-
density surface of the Rtt109 Lys-Ac-CoA binding tunnel, with (a) electrostatic potential 
mapping on the receptor and steric/electrostatic fields on the ligand; (b) hydrogen 
bonding potential mapping on the receptor and hydrogen-bond donor and acceptor fields 
on the ligand; and (c) lipophilic potential mapping on the receptor and hydrophobic fields 
on the ligand.  For receptor surface mapping: (a) red = positive electrostatic potential; 
blue = negative electrostatic potential; (b) red = H-bond donor, low electronegativity; 
blue = H-bond receptor, high electronegativity; gray = no H-bonding; (c) brown = highest 
lipophilicity; blue = highest hydrophilicity.  For colored polyhedra on the ligand: (a) red 
= negative electrostatic potential; blue = positive electrostatic potential; yellow = 
negative steric potential; green = positive steric potential; (b) cyan = H-bond donors 
favored; purple = H-bond donorsdisfavored; magenta = H-bond acceptors favored; red = 
H-bond acceptors disfavored; and (c) brown = high hydrophobicity; gray = high 
hydrophilicity (or hydrophobicity disfavored). 
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5.4 (a)  
 
?
 
5.4 (b) 
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5.4 (c) 
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5.4 Concluding Remarks 
With the available activity data at the time when we built the models, predictive 
and self-consistent CoMFA and CoMSIA models were derived for a series of thiourea-
based compounds; these 3D-QSAR hypotheses were expected to prove useful for the 
design and refinement of structurally related compounds and are expected to predict 
biological activities of similar structures with sufficient accuracy. Although in the follow-
up interference assays and orthogonal slot blot assays, the majority of the thiourea-based 
compounds used to build the models may have been identified as false-positives, our 3D-
QSAR analysis yielded color contour maps that match structural features in the 
experimental Rtt109 X-ray structure quite well, most notably highlighting steric 
constraints in the Lys-AcCoA binding tunnel and hydrophobic requirements for Rtt109 
inhibition, and pointing to key hydrogen-bonding interactions with Thr193 and Arg194 
that are expected to increase activity. 
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CHAPTER 6: 
PHARMACOPHORE MODELING STUDIES ON RTT109 INHIBITORS 
 
6.1 Introduction 
Pharmacophore is an abstract representation of the key features common to a 
set of active compounds that interact with the complementary sites on the corresponding 
receptor.109 Pharmacophore mapping has proven useful for identifying chemical 
functionalities responsible for biological activity and for pinpointing new drug and probe 
scaffolds via chemical database searching.109 Successful stories can be found in many 
medicinal chemistry publications, including the discoveries of the Type 1 11-β-
Hydroxysteroid dehydrogenase (11-β-HSD1) inhibitors,110 Hepatitis C virus NS5B 
protein inhibitors,111 hormone sensitive lipase inhibitors,112 anthrax lethal factor 
inhibitors,113 and compounds with strong affinity for various G-coupled protein 
receptors.114 Pharmacophores can also be applied to model the disruption of protein-
protein interactions. For example, without knowing the exact structural information 
related to the protein-protein interactions, pharmacophore models generated based on 
known disruptors of the c-Myc-Max dimer were able to identify nine novel disruptors in 
in vitro and in cellular assays.115 
6.1.1 GALAHAD Methodology 
Various pharmacophore elucidation programs are available and widely used, 
including CATALYST,116 GALAHAD,117 the pharmacophore module of MOE118, and 
PHASE.119 All were designed to address three core problems in the pharmacophore 
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elucidation: 1) representing the pharmacophoric features, 2) searching for potential 
alignments among the input active compounds, and 3) scoring and ranking these 
alignments.   
GALAHAD is one of the pharmacophore elucidation algorithms we used in our 
studies. It is short for a Genetic Algorithm with Linear Assignment for Hyper-molecular 
Alignment of Datasets.117, 120 In GALAHAD, the default pharmacophoric feature types 
are hydrogen bond donor and acceptor atoms (D and A), positive nitrogen (P), negative 
and hydrophobic centers (N and H), and steric features (S). GALAHAD divides the 
pharmacophore elucidation into two stages. It first utilizes a genetic algorithm (GA) to 
explore the ligand torsional space and to find a set of ligand conformations that have low 
steric energy, large common volume/shape, and high similarity in pharmacophoric 
features. GALAHAD then uses the extended LAMDA121 (Linear Assignment for 
Molecular Dataset Alignment) algorithm to perform a final alignment of ligands, of 
which conformations are held rigid from the first step. In the first stage, a multi-objective 
fitness Pareto function in the GA process is used to produce a population of possible 
models, each representing a different trade-off between the competing criteria (strain 
energy, volume overlap, and feature matching).122 The Pareto scoring function is a 
significant improvement over functions implemented in other earlier pharmacophore 
mapping algorithms. During the second stage, the LAMDA algorithm is extended beyond 
just a pair-wise atom-based alignment method. The extended LAMDA aligns datasets of 
two or more molecules based on shared features and the generation of a hyper-molecule 
and it does not require a template molecule for alignment. A hyper-molecule of a dataset 
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is produced by overlaying pairs of molecules or hyper-molecules and merging features of 
the same type that lie closely (the default threshold distance being 0.6 Å) while 
preserving the connectivity and geometry of each molecule in the dataset. This hyper-
molecule identifies the most important common substructures and conformations 
between a set of molecules and provides alignment rules for molecules not previously 
included in its generation.  
        In our studies, we used GALAHAD as the primary pharmacophore mapping tool to 
identify key features of the active compounds that contribute to their activities against 
Rtt109.  
 
6.2 Experimental Section 
6.2.1 Pharmacophore Modeling 
In HTS1 (See Chapter 2), 213 compounds (dataset ITB) were confirmed via dose-
response to be active against Rtt109, with activity ranging from 0.49 – 17.5 µM, while 
the 137 compounds displayed questionable dose-response curves and were classified as 
inactive. A structurally diverse subset of two hundred small molecules was selected (by 
Tanimoto coefficient123) from among the 82,648 inactives (82,511 compounds from the 
primary screen which displayed <50% inhibition, and 137 designated inactives from the 
dose-response screen) and was assembled into validation control database ITC. 
The 213 active compounds from our experimental HTS1 were clustered into 
eleven subgroups (datasets ITB1-ITB11) according to Tanimoto similarity with an 
average number of 20 compounds per cluster using SciTegic Pipeline Pilot 8.0 (Accelrys, 
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Inc.). Clustering was done by maximizing Tanimoto distance between cluster centers 
while minimizing that distance within each cluster. As described above, the two hundred 
compounds comprising inactive control dataset ITC were chosen from HTS-identified 
inactives using Tanimoto-based diverse subset selection in Pipeline Pilot. Three-
dimensional conformations of all dataset structures were generated via geometry 
optimization by energy minimization in Pipeline Pilot. All pharmacophore models were 
generated, analyzed, and optimized using genetic algorithms and Pareto scoring as 
implemented in the GALAHAD module (SYBYL-x/1.0). Models were obtained by 
iterating for a maximum of 40 generations with a population size of 35. A 40% mutation 
rate per torsional angle gene and a 100% crossover rate were applied in each GALAHAD 
run. Two key aromatic features were required to be present in all models in order to 
maximize enrichment index (EI) values; among remaining features, partial matching was 
enabled so that identified compounds must match at least the total number minus one (N-
1) of all features. 
 
6.3 Results and Discussion 
6.3.1 Pharmacophore Modeling 
The 213 active compounds comprising dataset ITB were divided into 11 
subsets (datasets ITB1 – ITB11) based on structural similarity as measured by Tanimoto 
coefficient.35 Seven of these subgroups comprised more than five structures; therefore, 
the five most active compounds, based on in vitro HTS1 Rtt109 IC50 values, from each of 
these groups were selected to create training sets to develop pharmacophore hypotheses 
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for each group. Additionally, the five most active compounds overall, i.e., across all 
eleven clusters in dataset ITB, were assembled into a general training set. Multiple 
pharmacophore hypotheses were generated for the seven clusters and for the general 
training set using genetic algorithms (GAs) and a scoring function based on Pareto multi-
objective optimization, as coded in the GALAHAD software module.117, 120, 121 For each 
hypothesis, a number of key criteria were obtained: specificity (a logarithmic indicator of 
the expected discrimination for each query, based on the number of features in the model, 
their partial match constraints, and distribution of the features in space);102 the number of 
training set compounds matching the pharmacophore; steric overlap; pharmacophoric 
concordance; and strain energy.120, 124 Models with high specificity values (and broader 
spatial distribution of features) are preferred, as nonspecific or ambiguous hypotheses 
generally cannot serve as effective database queries. The accuracy of each model was 
assessed by a multi-objective triage approach, in which hypotheses were first assigned a 
Pareto score, which is the number of other models obtained for the same training set that 
are judged superior to it in terms of total strain energy, steric overlap, pharmacophoric 
concordance, and tuplet agreement. If Pareto scores were identical, models were then 
ranked by Borda tally across pharmacophoric and steric multiplet consensus terms.102 In 
exceptional cases where top-ranked models (according to Borda sum) may have been 
questionable because they only matched two or three training set compounds, models 
were instead prioritized using specificity and number of compounds matched as key 
criteria. Any remaining “ties” were then broken in favor of hypotheses with lower overall 
energy.   
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6.3.2 Model Validation 
All eight final hypotheses – the general model, plus seven models from each 
compound subset – were validated by means of virtual database screening, in which the 
hypotheses were represented as UNITY queries (SYBYL 8.0, Tripos, Inc.) and 
subsequently used to search active compound database ITB and inactive control database 
ITC.  In the database screen, partial match criteria were established (see 6.2 
Experimental Section above), as requiring all features in a given model to be matched in 
order for a given compound to be considered a “hit” may result in false negatives, 
especially in the current case where the active Rtt109 inhibitors are structurally diverse 
and may interact with various sub-regions in the target binding area. The predictive 
ability of each hypothesis was assessed by the number of actives and inactives returned 
by that model, and by enrichment index EI, which represents the ratio of correctly 
identified actives to incorrectly identified inactives:?
€ 
EI = IactiveDactive •
Dinactive
Iinactive                         (1) 
where Iactive is the number of active compounds returned by the pharmacophore model 
query; Iinactive is the nonzero number of inactive compounds returned by the query, i.e., 
incorrect matches; Dactive is the number of structures in the active compound database 
ITB (213); and Dinactive is the number of structures in the inactive control database ITC 
(200).125 Results from this screen are shown in Table 6.1: the four hypotheses H1-H4 
(derived from the general training set and datasets ITB1, ITB5, and ITB11, respectively) 
returned few or no inactive compounds. (Four models from the remaining structural 
subgroups ITB3, ITB4, ITB6 and ITB7 erroneously matched a large number of 
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inactives, i.e., were nonspecific, and were therefore excluded from further consideration.) 
The general model H1 retrieved the highest number of actives (107, 50.23% of ITB 
compounds) from among the four feasible hypotheses, but also returned 12 false positives 
(6% of ITC structures), resulting in a relatively low enrichment index of 8.37.  Model H2 
yielded a much higher enrichment index (30.99) but was able to identify only thirty-three 
active compounds. Similarly, hypothesis H3 from dataset ITB5 demonstrated the highest 
enrichment index (36.62), identifying only one inactive compound out of 200, but 
returned only thirty-nine actives. Note that an enrichment index could not be calculated 
for model H4, as it returned no inactive structures; however, this hypothesis pinpointed 
even fewer actives: only twenty out of 213. Model H1 was therefore chosen as the 
preferred pharmacophore hypothesis.  
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Table 6.1. Pharmacophore model validation results, obtained by screening active 
compound database ITB and inactive compound database ITC using four hypotheses 
H1-H4 
 
aEnrichment index 
Model  Actives Matched (Number, 
Percent of Total) 
Inactives Matched (Number, 
Percent of Total) 
EIa 
H1 107/213, 50.23% 12/200, 6.00% 8.37 
H2 33/213, 15.49% 1/200, 0.50% 30.99 
H3 39/213, 18.31% 1/200, 0.50% 36.62 
H4 20/213, 9.39% 0, 0.00%  N/A 
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Graphical renderings of models H1-H4 are shown in Figure 6.1. The general model 
H1 (Figure 6.1a), derived from the five most active Rtt109 inhibitors we tested, 
comprises five features: two hydrogen bond acceptors, two aromatic/hydrophobic 
features and one hydrophobic feature. The other three models (H2-H4, Figure 6.1b-6.1d), 
all incorporate the two hydrophobic/aromatic features seen in model H1, but vary 
significantly in terms of hydrogen-bond donor and acceptor positioning, which is not 
surprising given the distinct structural dissimilarity across the compound training subsets. 
Note, however, that a centrally positioned hydrophobic feature is present in all models 
except H3 (although the distance between this feature and the two hydrophobic/aromatic 
features varies somewhat, especially in the case of model H4). These shared 
pharmacophoric features suggest that the compounds in all four of these subgroups, 
although structurally diverse, may exhibit similar Rtt109 binding modes. 
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Figure 6.1. Pharmacophore hypotheses generated from four active Rtt109 inhibitor 
subsets: (a) H1, from the general training set; (b) H2, from subset ITB1; (c) H3, from 
subset ITB5; and (d) H4, from subset ITB11, shown with representative structures used 
to derive the models. (SYBYL-x/1.0, Tripos, Inc.) Features are colored as follows: cyan = 
hydrophobic; green = hydrogen-bond acceptor; magenta = hydrogen-bond donor; yellow 
= aromatic). 
6.1 (a)  
 
 
6.1 (b)  
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6.1 (c) 
 
 
 
6.1 (d) 
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6.3.3 Model Complementarity with the Rtt109 Active Site and 3D-QSAR Models 
To assess the compatibility of model H1 with experimentally determined 
structural features in the lysine-AcCoA tunnel, the pharmacophoric features of this model 
were superimposed upon this area in the Rtt109 X-ray structure (2ZFN.pdb.31) The most 
active compound (6.1, GPHR-00049940, see Table 6.2) identified by our HTS1 assay 
was docked into the Lys-AcCoA binding tunnel (Surflex-Dock, SYBYL 8.0, Tripos, 
Inc.), and its predicted bound conformation is illustrated in Figure 6.2 together with 
model H1 and nearby residues in the Rtt109 crystal structure. All three demonstrate good 
agreement, further supporting the hypothesis that the inhibitors pinpointed in our 
experimental screen bind to Rtt109 in the lysine tunnel area. The hydrophobic/aromatic 
feature HY2_ARO6 in model H1 represents moieties that can engage in hydrophobic 
interactions with nearby aliphatic portions of the Rtt109 Lys87 and Arg194 side chains, 
as well as with Tyr199 and Phe84, and this feature may also signify a π-π interaction with 
Tyr199. The hydrogen-bonding features AA1 and AA4 are found in the vicinity of 
Trp222 and Ala88, respectively, indicating that inhibitor activity may be enhanced by 
hydrogen-bonding groups in those locations that can interact with the amino moieties of 
Trp222 and Ala88. Furthermore, the hydrophobic/aromatic feature HY_5_ARO7 points 
to one or more inhibitor functionalities that can accommodate the hydrophobic 
environment formed by Lys210, Ile212, Leu218, and Trp221. Notably, key residues such 
as Arg194, Lys210, Ile212, and Trp221, pinpointed by the pharmacophore models were 
also identified by 3D-QSAR models as the important residues for inhibitor binding. The 
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consistency between the 3D-QSAR models and pharmacophore maps serves as 
supporting evidence that the compounds may bind to the Lys-AcCoA tunnel of Rtt109. 
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Table 6.2. General training set comprising the five most active compounds overall from 
dataset ITB, used to generate pharmacophore model H1, with Rtt109 activity values 
Compound # Structure Compound ID Rtt109 IC50 (µM) 
6.1 
 
GPHR-00049940 0.49 ± 0.02 
6.2 
 
GPHR-00032548 0.71 ± 0.05 
6.3 
 
GPHR-00052071 0.90 ± 0.21 
6.4 
 
GPHR-00054718 0.91 ± 0.22 
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6.5 
 
GPHR-00050689 0.97 ± 0.29 
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Figure 6.2. Final Rtt109 inhibitor pharmacophore model H1 based on the five most 
potent compounds overall as identified by experimental HTS, shown with the predicted 
bound conformation of most active compound 6.1(GPHR-00049940) and nearby residues 
in the Rtt109 Lys-Ac-CoA binding region (2ZFN.pdb31). (SYBYL-x/1.0, Tripos, Inc.) 
Features are colored as follows: cyan = hydrophobic; green = hydrogen-bondacceptor; 
magenta = hydrogen-bond donor; yellow = aromatic). 
 
 
 
  112 
6.4 Concluding Remarks 
Novel, genetic algorithm-based pharmacophore hypotheses were developed and 
validated using various subsets of active compounds based on HTS1, which elucidate key 
hydrogen bonding and hydrophobic/aromatic requirements for successful Rtt109 
inhibition, and which can also be used to search in silico compound databases to identify 
additional novel scaffold structures. With further studies of the active compounds, 
including the follow-up interference assays and orthogonal slot blot assays, the majority 
of the active compounds used to build the models may have substequently been identified 
as false-positives. However, the pharmacophore hypotheses point to critical receptor 
residues demonstrated by experiments, including Tyr199 and Trp222 that are predicted to 
participate in small-molecule binding, which may provide insight into potential 
mechanisms of Rtt109 inhibition. Most notably, features in the best pharmacophore 
hypotheses and 3D-QSAR models derived from our HTS1 actives exhibit high 
complementarity, and closely match steric, electrostatic, hydrogen-bonding and 
hydrophobic features in the Rtt109 X-ray structure (2ZFN.pdb31), supporting the 
hypothesis that these compounds bind at the lysine entrance tunnel.  It will nevertheless 
be important to experimentally confirm our predicted Rtt109 inhibitor binding modes via 
compound cocrystallization. 
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CHAPTER 7: 
CLASSIFICATION OF HIGHLY UNBALANCED RTT109 ACTIVITY DATA USING 
A COST SENSITIVE SUPPORT VECTOR MACHINE TECHNIQUE 
 
7.1 Introduction 
The Support Vector Machine (SVM) is a popular and effective classification 
algorithm. Intuitively, the general idea behind SVM is to present the examples as points 
in the feature space and separate them with a large gap (margin).126 In the 
cheminformatics field, the features that represent compounds are usually their structural 
and physicochemical properties, including molecular weight, logP, area of van der Waals 
surface, polar surface area, connectivity and shape indices, and so on.  
7.1.1 Geometric Margins and the General SVM Algorithm 
In the following figure Figure 7.1, red dots represent positive training examples 
(y(i) = 1), e.g., the actives, and blue dots denote negative training examples (y(i) = -1), e.g., 
the inactives. The features X1 and X2 can be the compounds’ molecular weight and logP. 
A decision boundary (ωTx+b = 0) is also shown. The point at A represents the input x(i) of 
positive training examples. Its distance to the decision boundary is denoted as γ(i), which 
is the geometric margin of (ω, b) with respect to a training example (x(i) , y(i)). The 
distance can be expressed as the following: 
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Figure 7.1. Illustration of a decision boundary (separating hyperplane)  
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For example, the geometric margin of (ω, b) with respect to the training set S = 
{(x(i) , y(i)); i = 1, …, m} is then defined as the smallest geometric margin on the 
individual training examples: 
 
The goal of the SVM algorithm is then to find a decision boundary that maximizes the 
geometric margin, which reflects a powerful classifier that can be used to make confident 
and correct predictions on the training examples.126, 127 This can be formalized as an 
optimization problem as follows: 
 
i.e., maximize the geometric margin γ, subject to the condition that each training example 
has geometric margins of at least γ. However, the “||ω|| = 1” constraint is non-convex and 
cannot be solved with the standard optimization method. Thus the problem needs to be 
transformed into the following one: 
 
By introducing a scaling constraint that  = 1, then the optimization can be further 
transformed: 
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Sometimes, the data may not be separable. In some other cases where outliers 
exist, finding a separating hyperplane may not offer us the best solution to our problem. 
In order to make the algorithm work for non-separable data and less sensitive to outliers, 
the optimization problem can be formulated with regularization terms: 
 
A cost Cξi will be paid for a mislabeled example. The parameter C determines the 
relative weighting between both the goals of keeping  ||ω||2 small and of making sure that 
most examples can be predicted correctly (with geometric margin at least 1), namely a 
trade-off between a large margin and a small classification error penalty.127 By using the 
Lagrangian multipliers, we obtain the dual form of the optimization problem: 
 
This dual problem can then be solved using computational tools. 
7.1.2 Kernels 
The input attributes of a problem can be mapped to some new sets of features that 
will be used in a classification algorithm. With a feature mapping expressed as φ, the 
corresponding kernel is defined as follows: 
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All the inner products <x, z> in the previously defined optimization problems can now be 
replaced with K(x,z). The advantage of this replacement is that K(x,z) may be 
inexpensive to calculate, even though the calculation of φ(x) may be very costly due to 
the fact it can be a high dimensional vector.127 Thus by using an efficient way to calculate 
K(x,z), SVM algorithms can classify examples in high dimensional space given the 
feature mapping φ, without explicitly representing vectors φ(x). This allows SVM 
algorithms to separate non-linearly separable data in a higher dimensional space. 
In the computer aided drug design field, the SVM algorithm can be used to 
generate ligand-based binary classification models. Unlike 3D QSAR models that usually 
depend on structurally related compounds to produce reliable results and unlike 
pharmacophore models that often rely on the information of the most active compounds, 
SVM models take much more experimental information into account by utilizing 
structural and activity information of all actives and inactives. Thus, we have built SVM 
classification models that complement our 3D-QSAR and pharmacophore models and 
that serve as an additional tool for identifying novel Rtt109 inhibitors.    
 
7.2 Experimental Section 
7.2.1 Data Sets 
The structures and activity information were from the HTS1 experiment, where 
we evaluated 82,861 compounds from our in-house collection for activity against Rtt109 
complex. The detailed assay description can be found in Chapter 2. 
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In HTS1, a total of 213 compounds (dataset ITB) were confirmed via dose-
response to be active against Rtt109 complex, with activity ranging from 0.49 – 17.5µM. 
A total of 40769 compounds (dataset ITD) with percentage inhibition of less than 40% 
were classified as inactives. The 200 compounds and 10528 compounds comprising 
inactive control dataset ITC and ITE respectively were chosen from ITD using the 
Tanimoto-based diverse subset selection in Pipeline Pilot.123 
7.2.2 Computational Methods 
7.2.2.1 3D Structure Generation 
Three-dimensional conformations of all dataset structures were generated via 
geometry optimization by energy minimization in Pipeline Pilot and were further 
geometry optimized in MOE.  
7.2.2.2 Descriptors Calculation 
 MOE descriptors. Molecular descriptors were used to quantitatively represent 
structural and physicochemical properties of compounds. A total of 334 both 2D and 3D 
molecular descriptors were calculated using MOE.128 These descriptors included physical 
properties, atom and bond counts, connectivity and shape indices, MOPAC descriptors, 
partial charge descriptors, pharmacophore feature descriptors, and so on. Details of the 
descriptors can be found in MOE manual or at 
http://www.chemcomp.com/journal/descr.htm. 
 Extended-Connectivity Fingerprints (ECFP). Extended-Connectivity Fingerprints 
are circular topological fingerprints based on the 2D structure of a compound.129 The 
ECFP descriptor generation process systematically collects the neighboring atoms of each 
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non-hydrogen atom within multiple circular layers up to a given diameter and assigns 
them integer codes (known as identifiers). Hash functions are then applied to the set of 
the resulting identifiers to produce the fixed-length binary representation that defines the 
extended-connectivity fingerprint. A diameter of six was used to calculate the ECFP-6 
descriptors for compounds used in our study. 
7.2.2.3 Data Set Division for Model Development and Validation 
Compounds in ITB and ITC were combined and randomly split into a training set 
(Train 1) of 330 compounds (170 actives and 160 inactives, 80% of ITB and ITC) and an 
external test set (Test 1) of 83 compounds (43 actives and 40 inactives, 20% of ITB and 
ITC). 
Because there are many more inactives than actives, ITB with a very limited 
number of diverse inactives may not be sufficient to represent the chemical space of the 
inactives. Studies have demonstrated that models built on a limited number of 
compounds are expected to have limited applicability and may result in unreliable 
predictions when applied to virtual screening of structurally diverse chemical 
databases.130, 131 The significantly larger number of inactives in the training set is 
expected to increase the applicability domain of the model and to reduce the rate of false 
positives. Therefore, we decided to include a much larger number of inactives in our 
training set. Similarly, compounds in ITB and ITE were merged and randomly split into a 
training set (Train 2) of 8592 compounds (170 actives and 8422 inactives, 80% of ITB 
and ITE) and an external test set (Test 2) of 2149 compounds which included 43 actives 
and 2106 inactives (20% of ITB and ITE). 
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7.2.2.4 Support Vector Machine 
In this study, all SVM models were built and optimized using the open source 
package RapidMiner.132 We used Gaussian Radial Basis Function as the kernel type? 
k(x(i), x(j))  =  exp (-γ||x(i) - x(j)||)2 
Parameters C and γ were optimized by maximizing the prediction accuracy in a 10-fold 
cross validation of the training data. Accuracy, sensitivity (recall, true positive rate), 
specificity (true negative rate), precision (positive predictive value, the number of true 
positives divided by the sum of true positives and false positives), and f measure (the 
harmonic mean of precision and recall) were employed to evaluate the prediction power 
of the model against the external test sets.  
 
7.3 Results and Discussion 
7.3.1 Model Performances 
Table 7.1 shows the internal predictive performances of the models based on the 
training set Train 1 by means of 10-fold cross-validation using MOE descriptors. The 
combination of C = 1.26 and γ = 0.01 yielded the model (Model 1) with the best cross-
validated accuracy of 96.97% for Train 1 using MOE descriptors. Model 1 demonstrated 
its predictive power through the performance on the blind test set Test 1 and the 
predicting results are displayed in Table 7.2. A total of 40 out of 40 inactives (100%) 
were accurately classified. Only 3 out of 40 inactives (6.12%) in Test 1 were incorrectly 
predicted to be inactives. 
We then analyzed the compounds that were predicted incorrectly in the 10-fold 
cross validation process and in the external evaluation of Model 1. Table 7.3 shows the 
structures of the misclassified compounds in the 10-fold validation process. By analyzing 
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their structures, it is easy to find that the obvious structural differences between some of 
these compounds and most of the actives may explain why they were predicted to be 
inactive. For example, there is almost no positive charged compound in the active set, 
and thus the positive charged N atom of compound GPHR-00032548 may be the reason 
why it was predicted to be inactive. Compound GPHR-00029897 contains a fused ring 
system and compound GPHR-00031010 contains many O atoms. Both structural 
properties are very rare in compounds in the active set. In the case of compound GPHR-
00058762, its size is much smaller than the majority of actives. As for compound GPHR-
00026937, it is the only active compound with a 6-member ring in the position 
connecting to the S atom among the compounds with the succinamide scaffold. Similarly, 
the misclassified compounds in the Test 1 set shown in Table 7.4 are structurally 
dissimilar to the most of the actives in Train 1. The size of GPHR-00044631 may be too 
small. Compound GPHR-00024372 contains several methoxy groups and compound 
GPHR-00027595 contains several hydroxyl groups, which are not present in the actives 
in Train 1. More information related to why these compounds are actives may be needed 
in order to predict these compounds correctly. It is also possible that some compounds 
are outliers that cannot be directly identified by SVM models. It is an interesting topic for 
future work. 
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Table 7.1. The performance of the internal 10-fold cross validation of the model (Model 
1) developed based on database Train 1 using MOE descriptors 
 
 true active true inactive class precision 
pred. active 160 0 100% 
pred. inactive 10 160 94.12% 
class recall 94.12% 100%  
C = 1.26, γ = 0.01, cross-validated accuracy = 96.97% 
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Table 7.2. The performance of the model (Model 1) developed based on database Train 1 
using MOE descriptors on the external test set Test 1 
 
 true active true inactive class precision 
pred. active 40 0 100% 
pred. inactive 3 40 93.02% 
class recall 93.02% 100%  
C = 1.26, γ = 0.01, accuracy = 96.39% 
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Table 7.3. The structures of the incorrectly predicted compounds in the 10-fold 
validation process of Model 1 
Structures Compound ID IC50 (µM) Prediction 
 
Image 
 
GPHR-00032548 0.55 inactive 
 
Image 
 
GPHR-00029897 1.28 inactive 
 
Image 
 
GPHR-00051573 1.43 inactive 
 
 
GPHR-00057665 1.7 inactive 
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Image 
 
GPHR-00058762 2.36 inactive 
 
Image 
 
GPHR-00031010 2.37 inactive 
 
Image 
 
GPHR-00001819 2.96 inactive 
 
Image 
 
GPHR-00003628 4.69 inactive 
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Image 
 
GPHR-00026937 6.73 inactive 
 
Image 
 
GPHR-00025780 7.77 inactive 
 
  127 
Table 7.4. The structures of incorrectly predicted compounds in the external validation of 
Model 1 using Test 1 
Structures Compound ID IC50 (µM) Prediction 
 
GPHR-00044631 3.25 inactive 
 
GPHR-00024372 4.41 inactive 
 
GPHR-00027595 5.74 inactive 
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A SVM model was also developed using the training set Train 1 with ECFP-6 
descriptors. The cross-validated accuracy, sensitivity, and specificity of the optimized 
model (Model 2) using ECFP-6 descriptors for Train 1 were 92.19%, 92.94%, and 
91.25%, respectively. The performance of the internal validation of Model 2 is worse 
than that of Model 1 and thus ECFP-6 descriptors were not used in the further model 
developing process. The internal evaluation results are summarized in Table 7.5. 
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Table 7.5. The performance of the internal 10-fold cross validation of the model (Model 
2) developed based on database Train 1 using ECFP-6 descriptors 
 
 true active true inactive class precision 
pred. active 158 14 91.86% 
pred. inactive 12 146 92.41% 
class recall 92.94% 91.25%  
C = 10.01, γ = 0.01, cross-validated accuracy = 92.19% 
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As mentioned in the section 7.2.2.3, in order to increase the applicability domain 
of SVM model, Train 2 which contains a much larger number of diverse inactives than 
Train 1 was used to train the SVM model. However, the significantly larger number of 
inactives (8422 inactives) compared to the number of actives (170 actives) in Train 2 
leads to a highly imbalanced data set. This biased data set will result in an SVM model 
that is biased towards prediction of the majority class (inactives) and will be poorly 
predictive for the actives. To resolve this problem, some techniques can be applied to 
cope with this imbalanced data set. One of the common techniques is to under-sample the 
majority class (inactives) in the training set. This is basically what we did for Train 1, 
which includes comparable numbers of actives and inactives. The drawback of this 
technique is that the reduction in data for model building will lead to loss of information 
and a limited application domain of the resulting model. Another technique is to increase 
the cost associated with misclassification of the minority class (actives). During our SVM 
model development and optimization process based on Train 2, a balanced cost was 
applied, i.e., a 49 times as much penalty will be paid for the misclassification of an active 
compound into an inactive compound compared to the misclassification of an inactive 
compound into an active compound. The performances of the model (Model 3) built on 
Train 2 using MOE descriptors and the balanced cost are displayed in Table 7.6. Its 
cross-validated accuracy, sensitivity, and specificity were 90.84%, 79.41%, and 91.07%, 
respectively. As you may notice, the sensitivity decreased dramatically compared to that 
of Model 1. This may be due to the fact that more inactives that are structurally similar to 
the actives were included in the training set. It is very challenging to discriminate 
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between actives and inactives with subtle structural differences. In order to make correct 
predictions, information related to why these small differences in the structure result in 
totally different activities may be needed. 
The performance of Model 3 on the external test set Test 2 is shown in Table 7.7. 
The overall prediction accuracy, sensitivity, and specificity are comparable to the 10-fold 
validated ones of Model 3. The results indicate that Model3 is able to retrieve the 
majority (76.74%) of the actives while rejecting 91.36% of the inactives. We then trained 
the SVM model with all compounds in ITB and ITE to build a comprehensive model 
(Model 4) for predicting compounds with unknown activities. Based on the 10-fold 
validation results shown in Table 7.8, Model 4 demonstrated robust predictive power by 
correctly identifying 84.51% of the actives and 90.40% of the inactives. 
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Table 7.6. The performance of the internal 10-fold cross validation of the model (Model 
3) developed based on database Train 2 using MOE descriptors 
 true active  true inactive class precision 
pred. active 135 (TP) 752 15.22% 
pred. inactive 35 7670 (TN) 99.55% 
class recall 79.41% 91.07%  
C = 1, γ = 0.001, cross-validated accuracy = 90.84% 
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Table 7.7. The performance of the model (Model 3) developed based on database Train 2 
using MOE descriptors on the external test set Test 2 
 
 true active  true inactive class precision 
pred. active 33 (TP) 192 14.67% 
pred. inactive 10 1924 (TN) 99.48% 
class recall 76.74% 91.36%  
C = 1, γ = 0.001, cross-validated accuracy = 90.84% 
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Table 7.8. The performance of the internal 10-fold cross validation of the model (Model 
4) developed based on database ITB and ITE using MOE descriptors 
 true active  true inactive class precision 
pred. active 180 (TP) 1011 15.11% 
pred. inactive 33 9517 (TN) 99.65% 
class recall 84.51% 90.40%  
C = 0.5, γ = 0.001, cross-validated accuracy = 90.28% 
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7.3.2 Analysis of Molecular Descriptors 
Several molecular descriptors have higher SVM kernel weights than others, 
suggesting they play more important roles in classifying actives and inactives. These 
descriptors for Model 4 are shown in Table 7.9 and the corresponding descriptor value 
distribution for the actives and inactives is displayed in Figure 7.2. We also noticed that 
the mean values of these descriptors for the actives had significant differences from those 
of the inactives.  In Model 4, descriptor a_nS, the number of S atoms, has a higher mean 
value for the actives than for the inactives while descriptors a_nCl, the number of Cl 
atoms, and a_nN, the number of N atoms have lower mean values for the actives than for 
the inactives. Figure 7.2 illustrates that the majority of inactives do not contain S atoms 
while most actives contain at least one S atom. As for the number of Cl atoms, although 
the difference between the mean values for actives and inactives is not large, the value 
distribution indicates that the inactives are more likely to have more than two Cl atoms 
than the actives. The value of the descriptor “reactive”, which represents the number of 
reactive groups, for actives is smaller than that for the inactives. The value distribution 
figures show that none of the actives contain reactive groups while a small portion of 
inactives contain one reactive group.  The value distribution figures also demonstrate that 
a higher percentage of inactives has one, three, or five N atoms than that of the actives. 
The PM3_LUMO descriptor shows the energy (eV) of the Lowest Unoccupied Molecular 
Orbital of compounds calculated using the PM3 method. The lower PM3_LUMO values 
for the actives indicate the actives are more electrophilic compared to the inactives. The 
TPSA, polar surface area (Å2), is well correlated with the oral bioavailability of drug 
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candidates.133 The average value of TPSA for actives is larger than that for inactives, 
suggesting that the actives are likely to have more solvent-exposed polar groups. The 
descriptor b_rotR is a rotatable bond related descriptor, and it has a higher mean value for 
the inactives than for the actives. It indicates that among the bonds between heavy atoms 
that the compounds have, there are more acyclic single bonds in inactive compounds than 
the actives, and the active compounds tend be more rigid compared to the inactives. MOE 
descriptors PEOE_VSA+2 and PEOE_VSA-1 are the sum of the accessible van der 
Waals surface area (in Å2) for each atom, of which partial charge is in the range [0.10, 
0.15) and [-0.10, -0.05) based on the Partial Equalization of Orbital Electronegativities 
(PEOE) method.103 PEOE_VSA+2 has a higher mean value for the actives while the 
PEOE_VSA-1 has a higher mean value for the inactives. Based on the value distribution 
in Figure 7.2, most actives and inactives have a PEOE_VSA+2 value ranging from 0 to 
20 Å2, but a larger portion of actives has a PEOE_VSA+2 value ranging from 20 to 60 Å2 
compared to that of the inactives. The majority of the actives and inactives has a 
PEOE_VSA-1 value ranging from 0 to 80 Å2, while a larger portion of inactives has a 
PEOE_VSA-1 value that is larger than 120 Å2. These results suggest that the actives 
contain more certain types of partially positively charged atoms and the inactives contain 
more certain types of partially negatively charged atoms. In addition, the average values 
of the estimated logP values for the actives are slightly larger than the inactives, 
indicating the actives are likely to be more hydrophobic than the inactives. As shown in 
Figure 7.2, the majority of both actives and inactives have an estimated logP value 
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ranging from 2 to 4, but a larger portion of actives has estimated logP values ranging 
from 4 to 6 than the inactives.  
  138 
Table 7.9. The representative important MOE descriptors in Model4 and their 
corresponding average values for actives and inactives in ITB and ITE 
MOE 
Descriptor 
Weight Average 
Value 
(Actives) 
Average 
Value 
(Inactives) 
Meaning 
a_nS  157.82 1.12 0.55 Number of sulfur atoms 
reactive -148.05 0.00 0.06 Indicator of the presence of reactive 
groups in a compound. The 
definition of reactive groups is 
based on the Oprea set134. The 
reactive groups include metals, 
phospho-, N/O/S-N/O/S single 
bonds, thiols, acyl halides, Michael 
Acceptors, azides, and esters. 
PM3_LUMO -124.85 -1.15 -0.79 The energy (eV) of the Lowest 
Unoccupied Molecular Orbital 
(LUMO) calculated using the 
PM3.135-137 
TPSA 123.42 83.41 
 
69.09 Polar surface area (Å2) calculated 
using group contributions to 
approximate the polar surface area 
from connection table information 
only and using the method of Ertl et 
al.138 
a_nCl -104.52 0.18 0.24 Number of chlorine atoms 
a_nN -101.74 2.47 2.56 Number of nitrogen atoms 
PEOE_VSA+2 95.00 17.92 12.80 The sum of van der Waals surface 
area (in Å2) for each atom, of which 
partial charge is in the range [0.10, 
0.15) based on the Partial 
Equalization of Orbital 
Electronegativities (PEOE) 
method.103 
PEOE_VSA-1 -88.83 54.61 57.74 The sum of van der Waals surface 
area (in Å2) for each atom, of which 
partial charge is in the range [-0.10, 
-0.05) based on the Partial 
Equalization of Orbital 
Electronegativities (PEOE) 
method.103 
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?
b_rotR -81.27 0.19 
 
0.22 Fraction of rotatable bonds, which 
is defined as the number of 
rotatable bonds divided by the 
number of bonds between heavy 
atoms. 
logP(o/w) 76.08 3.58 3.17 Log of the octanol/water partition 
coefficient (including implicit 
hydrogens) calculated from a linear 
atom type model with r2 = 0.931, 
RMSE=0.393 that was trained using 
1,827 molecules.128 
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Figure 7.2. The representative important MOE descriptor property distribution profiles 
for 213 Rtt109-complex inhibitors (magenta, right), compared to 10528 inactives (blue, 
left) 
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7.3.3 Application of Model for the Virtual Screening to Identify Novel Rtt109 Inhibitors 
The comprehensive model (Model 4) built based on the database ITB and ITE 
should be useful for novel Rtt109 inhibitor discovery because of the model’s robust 
internal predictive power. We applied this model to screen the virtual database of FDA 
approved drugs for humans. The top 20 compounds with a prediction confidence larger 
than 0.6 are listed in Table 7.10. One obvious property these compounds share with the 
actives is that they contain at least one S atom. In addition, some of these compounds 
have the hydrophobic/aromatic and acceptor features that were pinpointed by the 
pharmacophore models, indicating consistency between the SVM and pharmacophore 
models. Notably, some of these predicted actives were reported as antibiotics and one of 
them has antifungal effects. If these compounds have Rtt109 inhibitory activities in the 
experimental assay, they may be able to be used as dual drugs with both antibiotic and 
antifungal effects or as drugs with different antifungal mechanisms.   
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Table 7.10. The top 20 compounds with a prediction confidence larger than 0.6 in the 
database of FDA approved drugs for humans 
Structures Name Drug Usage Confidence 
(active) 
 
Image 
 
Nobecutan Antiseptic 0.81 
 
Image 
 
Tetramethylthiuram 
monosulfide 
Antifungal 0.76 
 
 
Thiaminum Vitamin 0.72 
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Image 
 
N-benzoyl-l-tyrosyl-paba Diagnostic Aid 0.70 
 
Image 
 
Sulfinpyrazone Antiurolithic 0.70 
 
Image 
 
Sulindac Antineoplastic 0.68 
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Image 
 
Troglitazone Antidiabetic 0.68 
 
Image 
 
Carprofen Anti-
inflammatory 
0.67 
 
Image 
 
Sucrose octaacetate, 
((alpha-d)-
fructofuranosyl)-isomer 
Phamaceutic Aid 0.66 
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Image 
 
Mezlocillin Antibiotic 0.65 
 
Image 
 
Sulfisoxazole acetal Antibacterial 0.64 
 
Image 
 
Ceftibuten Antibiotic 0.63 
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Image 
 
Cephalothin Antibiotic 0.63 
 
 
 
Tiagabine Anticonvulsant 0.63 
 
Image 
 
Iopanoic acid Diagnostic Aid 0.62 
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Image 
 
Ethoxazolamide Diuretic 0.62 
 
Image 
 
Cefotaxime Antibiotic 0.62 
 
Image 
 
Cefoxitin Antibiotic 0.62 
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Image 
 
Cefazolin Antibiotic 0.61 
 
Image 
 
Eprosartan Antihypertensive 0.61 
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7.4 Concluding Remarks 
Different SVM models suitable for virtual screening purposes without the 
knowledge of 3D information of the protein target were developed from Rtt109 inhibitors 
with experimental biological activity data. These models were validated using internal 
validation with 10-fold cross-validation and external validation with compounds not used 
in the model development. A model (Model 1) with the MOE descriptors based on the 
randomly split balanced training set yielded the highest cross-validated accuracy, 96.97% 
on the internal test set. It achieved an accuracy of 96.39% on a heterogeneous external 
test set. A comprehensive model (Model 4) with the MOE descriptors based on 213 
actives and 10528 inactives was developed in order to expand the application domain of 
the model. Its 10-fold cross-validated accuracy was 90.28%. It is expected to retrieve 
84.51% actives and reject 90.40% inactives based on its performance in the internal 
validation process. 
Several molecular descriptors including the number of S atoms, Cl atoms, N 
atoms, reactive groups, the energy of the Lowest Unoccupied Molecular Orbital, polar 
surface area, partial charge distribution, rotatable bonds, and logP(o/w), may play a 
critical role in defining Rtt109inhibitory activities. These important descriptors indicated 
specific atomic, partial charge, and other property requirements for Rtt109inhibitors. 
In summary, we have developed internally validated and externally predictive 
SVM models for Rtt109 inhibitory activities based on HTS1. Although utilizing different 
methodology, SVM, 3D-QSAR, and pharmacophore models all were able to accurately 
predict activities of compounds and agreed with each other. These models presented in 
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this work are of potential use to complement HTS in screening chemical libraries and 
identifying novel Rtt109 inhibitors. However, further follow-up experiments may 
indicate some of the actives used in the model development may be false positives due to 
their interference with the assay reagents. In future work, further validated experimental 
activity data will be needed to verify and refine SVM models. 
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APPENDIX ONE:  
In vitro HTS1 Assay Data for the Fourteen Active, Thiourea-based Rtt109 Inhibitors 
from the Final 3D-QSAR Compound Training Set Shown in Table 5.1 (Hill: Hill slope 
which describes the steepness of the dose-response curve) 
 
No. 5.1 
 
 
Compound ID GPHR-00029275 
R2 0.97 
Hill 0.69 
IC50 1.73 µM 
n 2 
SE 0.46 µM 
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No. 5.2?
 
 
Compound ID GPHR-00026554 
R2 0.98 
Hill 2.26 
IC50 2.01 µM 
n 2 
SE 0.35 µM 
 
  165 
No.5.3 
 
 
Compound ID GPHR-00006279 
R2 0.98 
Hill 2.53 
IC50 2.96 µM 
n 2 
SE 0.68 µM 
 
  166 
No. 5.4 
 
 
Compound ID GPHR-00022505 
R2 0.97 
Hill 1.70 
IC50 3.22 µM 
n 2 
SE 0.84 µM 
 
 
  167 
No. 5.6 
 
 
Compound ID GPHR-00023078 
R2 0.98 
Hill 2.48 
IC50 3.89 µM 
n 2 
SE 1.49 µM 
 
  168 
No. 5.7 
 
 
Compound ID GPHR-00053677 
R2 0.97 
Hill 1.56 
IC50 4.40 µM 
n 2 
SE 1.30 µM 
 
  169 
No. 5.8 
 
 
Compound ID GPHR-00011814 
R2 0.98 
Hill 1.73 
IC50 4.82 µM 
n 2 
SE 1.38 µM 
 
  170 
No. 5.9 
 
 
Compound ID GPHR-00029320 
R2 0.96 
Hill 1.65 
IC50 5.04 µM 
n 2 
SE 2.09 µM 
 
  171 
No. 5.10 
 
 
Compound ID GPHR-00029429 
R2 0.96 
Hill 1.48 
IC50 5.30 µM 
n 2 
SE 2.14 µM 
 
  172 
No. 5.11 
 
 
Compound ID GPHR-00058009 
R2 0.93 
Hill 1.39 
IC50 5.32 µM 
n 2 
SE 2.09 µM 
 
  173 
 No. 5.12 
 
 
Compound ID GPHR-00029520 
R2 0.97 
Hill 1.69 
IC50 6.36 µM 
n 2 
SE 2.34 µM 
 
  174 
No. 5.13 
 
 
Compound ID GPHR-00031245 
R2 0.97 
Hill 1.43 
IC50 7.13 µM 
n 2  
SE 2.30 µM 
 
  175 
No. 5.14 
 
 
Compound ID GPHR-00029708 
R2 0.95 
Hill 1.55 
IC50 11.46 µM 
n 2 
SE 3.55 µM 
  176 
APPENDIX TWO:  
In vitro HTS1 Assay Data for the Five Most Active Compounds Overall from Dataset 
ITB, Used to Generate Pharmacophore Model H1 (Hill: Hill slope which describes the 
steepness of the dose-response curve)?
No.6.1 
?
 
Compound ID GPHR-00049940 
R2 0.99 
Hill 18.05 
IC50 0.49 µM 
n 2 
SE 0.02 µM?
 
  177 
No. 6.2 
 
 
Compound ID GPHR-00032548 
R2 1.00 
Hill 2.33 
IC50 0.71 µM 
n 2 
SE 0.05 µM 
 
  178 
No. 6.3 
 
 
Compound ID GPHR-00052071 
R2 0.99 
Hill 1.96 
IC50 0.90 µM 
n 2 
SE 0.21 µM 
 
  179 
No. 6.4 
?
 
Compound ID GPHR-00054718 
R2 0.99 
Hill 1.79 
IC50 0.91 µM 
n 2 
SE 0.22 µM 
 
  180 
No. 6.5 
 
 
 
 
Compound ID GPHR-00050689 
R2 0.98 
Hill 2.13 
IC50 0.97 µM 
n 2 
SE 0.29 µM 
 
